Novel CTLA4-IG immunoadhesin

By introducing specific amino acid modifications into CTLA4-Ig immunoadhesin, the binding ability to B7-1 and B7-2 is enhanced, and the problem of the inefficiency of the existing CTLA4-Ig immunoadhesin in inhibiting T cell activation is solved. Strengthen T cell inhibitory activity and better therapeutic effects were achieved.

CN113372451BActive Publication Date: 2024-12-03XENCOR INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202110326502.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2010-11-10
Filing Date
2011-02-22
Publication Date
2024-12-03
Estimated Expiration
2031-02-22

AI Technical Summary

Technical Problem

Existing CTLA4-Ig immunoadhesins are inefficient in inhibiting B7-mediated costimulatory, especially with the inferior affinity for B7-2, resulting in poor efficacy in transplant rejection and other autoimmune diseases treatments.

Method used

A novel CTLA4-Ig immunoadhesin was designed to enhance its binding affinity for B7-1 and B7-2 by introducing specific amino acid modifications into the CTLA4 protein, including variant CTLA4 protein and Ig Fc portion The combination of the combination, including amino acid substitutions such as A29H, T51N, L61E and K93Q, improves the binding ability of B7-1 and B7-2.

Benefits of technology

It significantly improved the T cell inhibitory activity of CTLA4-Ig immunoadhesin and the binding affinity of B7-1 and B7-2, and enhanced its efficacy in the treatment of immune-related diseases, especially in rheumatoid arthritis, It shows better results in the treatment of diseases such as systemic lupus erythematosus.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0002994854120000551
    Figure BDA0002994854120000551
  • Figure BDA0002994854120000561
    Figure BDA0002994854120000561
  • Figure BDA0002994854120000571
    Figure BDA0002994854120000571
Patent Text Reader

Abstract

The present application relates to CTLA4-Ig immunoadhesins targeting CD80 and CD86 and their uses, in particular for therapeutic purposes.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application. The application date of the original application is February 22, 2011, the application number is 201180019721.1 (international application number: PCT / US2011 / 025747, the divisional application number: 201610569505.9), and the name of the invention is “Novel CTLA4-IG immunoadhesin”.

[0002] This application claims the benefit under 35 USC §119(e) of USSN 61 / 412,309, filed November 10, 2010; USSN 61 / 334,806, filed May 14, 2010; and USSN 61 / 306,311, filed February 19, 2010, which are incorporated herein by reference in their entireties. Field of the Invention

[0003] The present application relates to CTLA4-Ig immunoadhesins targeting CD80 and CD86 and uses thereof, in particular for therapeutic purposes. Background of the Invention

[0004] T lymphocytes play a key role in the adaptive immune response to antigens. The T cells used for the first test need two signals to fully activate them (Bretscher 1999, Proc Natl Acad Sci USA 96: 185-90). The first signal is antigen-specific, provided by the interaction of the MHC / peptide complex on the T cell receptor (TCR) and the antigen presenting cell (APC). The second signal is a co-stimulatory signal provided by the interaction between the receptor on the T cell and its ligand on the APC. The engagement of the two TCR / MHC interactions and co-stimulatory interactions leads to T cell activation via a variety of intracellular pathways, including calcium-calmodulin and RAS mitogen-activated protein kinases, and the activation of transcription factors including a variety of effector compounds of cytokines such as IL-2. These events lead to T cell proliferation, CD4 + T helper cells (T H ) pool generation and activation of CD8 + Expansion of cytotoxic T cells. Not only is co-stimulation critical for full T cell activation, its absence during TCR / MHC engagement leads to anergy and / or apoptosis.

[0005] Although a variety of positive and negative co-stimulatory pathways are involved in T cell regulation, the most critical is the co-stimulatory pathway between CD28 on T cells and B7-1 (CD80) and B7-2 (CD86) on APC. CD28 promotes T cell differentiation into TH1 phenotype cells and enhances antibody production of B cells and activation of T cells. B7-1 and B7-2 expressed on APCs such as dendritic cells (DCs) and B cells have overlapping but different functions. B7-2 is constitutively expressed and is rapidly upregulated on APCs in concert with TCR / MHC engagement (signal 1). B7-1 expression is very low on resting cells, but is usually induced after long-term T cell stimulation. These differences suggest that, although B7-2 may be important at the initiation of T cell activation, B7-1 may play a greater role in perpetuating immune responses.

[0006] Upon T cell activation, the negative regulatory receptor cytotoxic T lymphocyte antigen 4 (CTLA4 or CTLA-4, also known as CD152) is upregulated on T cells (Alegre et al., 2001, Nat Rev Immunol 1:220-8). CTLA4 is structurally homologous to CD28, but binds both B7-1 and B7-2 ligands more tightly. CLTA4 inhibits immune responses in two major ways—it competes with CD28 for B7 ligands, thereby blocking co-stimulation, and it also negatively transmits signals to inhibit T cell activation (Krummel and Allison, 1995, J Exp Med 182:459-465; Walunas et al., 1994, Immunity 1:405-413). Recent studies have shown that B7-2 engages CD28 more than CTLA4 at the immune synapse, whereas B7-1 ligates CTLA4 more than CD28 (Collins et al., 2002, Immunity 17:201-210; Jansson et al., 2005, J Immunol 175:1575-1585).

[0007] Due to the critical role of the B7 co-stimulatory pathway in promoting and maintaining immune responses, therapeutic agents designed to antagonize it are promising for the treatment of autoimmune diseases and disorders. It is a CTLA4-Ig immunoadhesin composed of the extracellular binding domain of CTLA4 connected to the Fc domain of human IgG. Abatacept was developed to inhibit B7-mediated co-stimulation (Bluestone et al., 2006, Immunity 24: 233-238), and is approved for the treatment of rheumatoid arthritis (RA) and clinical trials for a variety of other autoimmune indications. However, although Abatacept shows some activity in the treatment of RA, it is ineffective for other indications. For example, CTLA4-Ig is much less effective in tolerance to transplant rejection (Kirk et al., 1997, Proc Natl Acad Sci USA 94: 8789-8794; Levisetti et al., 1997, J Immunol 159: 5187-5191).

[0008] The inadequate clinical performance of abatacept has been attributed to the suboptimal affinity of its native CTLA4 for B7 ligands, particularly B7-2 (due to the presumed importance of B7-2 in immune initiation). The present invention provides novel variant CTLA4-Ig immunoadhesins with improved B7 affinity and enhanced T cell inhibitory activity. Such novel immunoadhesins are of benefit in a variety of applications, particularly for the treatment of immune-related disorders, as discussed in detail below. SUMMARY OF THE INVENTION

[0009] The present invention provides novel CTLA4-Ig immunoadhesins that inhibit the interaction between antigen presenting cells (APCs) and T cells. The CTLA4-Ig immunoadhesins of the present invention include a CTLA4 portion that binds to human B7-1 (CD80) and B7-2 (CD86) with high affinity, and an Ig Fc portion (or Fc region) that can bind to one or more Fc receptors or Fc ligands.

[0010] In one aspect of the invention, the CTLA4-Ig immunoadhesin comprises a variant CTLA4 protein, wherein the variant comprises at least one amino acid modification in a native CTLA4 protein, wherein the modification is selected from the group consisting of A29E, A29F, A29H, A29K, A29N, A29Q, A29R, T30E, T30H, T30R, T30V, E31D, E31I, E31M, E31T, E31V, R33E, R33F, R33I, R33L, R33M, R33Q, R 33T, R33W, R33Y, T35D, T35E, T35F, T35M, T35V, T35Y, A49D, A49E, A49F, A49T, A49W, A49Y, T51D, T51E, T51H, T51 L, T51N, T51Q, T51R, T51S, T51V, M53E, M53F, M53H, M53Q, M53W, M53Y, T59H, T59I, T59L, T59N, T59Q, T59V, T59Y, L 61A, L61D, L61E, L61F, L61G, L61H, L61I, L61K, L61M, L61N, L61P, L61Q, L61R, L61S, L61T, L61V, L61W, L61Y, D63 E, S64K, S64R, S64Y, K93D, K93E, K93F, K93H, K93N, K93Q, K93R, K93S, K93T, K93V, K93W, K93Y, E95D, E95H, E95L, E 95Q, E95Y, M97D, M97F, M97I, M97N, M97V, Y98F, Y98W, Y102F, Y102W, Y103D, Y103E, Y103F, Y103H, Y103N, Y103Q, Y103W, L104F, L104H, L104M, L104V, L104Y, G105D, G105E, I106E and I106Y, wherein the substitution provides enhanced binding to B7-1 and / or B7-2. In a preferred aspect of the invention, the CTLA4-Ig immunoadhesin comprises a CTLA4 substitution selected from the group consisting of A29H, T51N, M53Y, L61E and K93Q, wherein the substitution provides enhanced binding to B7-1 and / or B7-2. In a most preferred aspect of the invention, the CTLA4-Ig immunoadhesin comprises a CTLA4 substitution selected from the group consisting of A29H, T51N, L61E, and K93Q, wherein said substitution provides enhanced binding to B7-1 and / or B7-2.In other aspects of the invention, the CTLA4-Ig immunoadhesin comprises a CTLA4 substitution selected from the group consisting of A29H, A29K, T51N, L61E and Y103Q, wherein the substitution provides enhanced binding to B7-1 and / or B7-2. In other aspects of the invention, the CTLA4-Ig immunoadhesin comprises a CTLA4 substitution selected from the group consisting of K93V, L61Q and L104H, wherein the substitution provides enhanced binding to B7-1 and / or B7-2.

[0011] In another aspect of the invention, the CTLA4-Ig immunoadhesin comprises a variant CTLA4 protein, wherein the variant comprises a protein selected from the group consisting of A29H / K93Q, A29H / M53Y, A29H / T51N, T51N / K93Q, T51N / M53Y, A29H / L61E / K93Q, A29H / M53Y / K93Q, A29H / M53Y / L61E, A29H / T51N / L61E, M53Y / L61E / K93Q, T51N / L61E / K93Q. 3Q, T51N / M53Y / L61E, A29H / M53Y / L61E / K93Q, A29H / T51N / L61E / K93Q, A29H / T51N / M53Y / K93Q, A29H / T51N / M53Y / L61E, T51N / M53Y / L61E / K93Q and A29H / T51N / M53Y / L61E / K93Q, wherein the variants provide enhanced binding to B7-1 and / or B7-2. In a preferred aspect of the invention, the CTLA4-Ig immunoadhesin comprises a combination of CTLA4 substitutions selected from the group consisting of T51N / L61E / K93Q and A29H / T51N / L61E / K93Q, wherein the variant provides enhanced binding to B7-1 and / or B7-2. In other aspects of the invention, the CTLA4-Ig immunoadhesin comprises a combination of CTLA4 substitutions selected from the group consisting of T51N / L61E / K93Q, A29H / T51N / L61E / K93Q, A29H / T51N, T51N / M53Y, and T51N / M53Y / L61E, wherein the variant provides enhanced binding to B7-1 and / or B7-2.

[0012] In another aspect of the invention, the CTLA4-Ig immunoadhesin comprises a variant CTLA4 protein, wherein the variant comprises a substitution at a CTLA4 position selected from the group consisting of 35, 49, 51, 53, 59, 61 and 95, wherein the variant provides enhanced binding to B7-1 and / or B7-2. In a preferred aspect of the invention, the CTLA4-Ig immunoadhesin comprises a variant CLTA4 protein, wherein the variant comprises a substitution at a CTLA4 position selected from the group consisting of 51 and 61, wherein the variant provides enhanced binding to B7-1 and / or B7-2.

[0013] In another aspect, the invention provides an immunoadhesin comprising a first domain comprising a variant human CTLA4 and a second domain comprising an IgG Fc region, wherein the first domain has the formula: Fx(1-28)-Vb(29)-Fx(30-50)-Vb(51)-Fx(52)-Vb(53)-Fx(54-60)-Vb(61)-Fx(62-92)-Vb(93)-Fx(94-124) [SEQ ID NO: 1], wherein Fx(1-28) is the sequence MHVAQPAVVLASSRGIASFVCEYASPGK (positions 1-28 of SEQ ID NO: 1); Vb(29) is selected from the group consisting of A and H; Fx(30-50) is the sequence TEVRVTVLRQADSQVTEVCAA (SEQ ID NO: 2 NO:1, positions 30-50); Vb(51) is selected from the group consisting of T and N; Fx(52) is Y; Vb(53) is selected from the group consisting of M and Y; Fx(54-60) is the sequence MGNELTF (SEQ ID NO:1, positions 54-60); Vb(61) is selected from the group consisting of L and E; Fx(62-92) is the sequence DDSICTGTSSGNQVNLTIQGLRAMDTGLYIC (SEQ ID NO:1, positions 62-92); Vb(93) is selected from the group consisting of K and Q; and Fx(94-124) is the sequence VELMYPPPYYLGIGNGTQIYVIDPEPCPDSD (SEQ ID NO:1, positions 94-124); wherein the variant comprises at least one amino acid modification compared to SEQ ID NO:6 and wherein the variant exhibits increased binding to B7-1, B7-2, or both B7-1 and B7-2.

[0014] In a further aspect, the invention provides an immunoadhesin comprising a first domain comprising a variant human CTLA4 and a second domain comprising an IgG Fc region, wherein the first domain has the formula: Fx(1-28)-Vb(29)-Fx(30-50)-Vb(51)-Fx(52)-Vb(53)-Fx(54-60)-Vb(61)-Fx(62-92)-Vb(93)-Fx(94-124) [SEQ ID NO:2], wherein Fx(1-28) is the sequence MHVAQPAVVLASSRGIASFVCEYASPGK (positions 1-28 of SEQ ID NO:2); Vb(29) is H; Fx(30-50) is the sequence TEVRVTVLRQADSQVTEVCAA (SEQ ID NO:2); NO:2, positions 30-50); Vb(51) is selected from the group consisting of T and N; Fx(52) is Y; Vb(53) is selected from the group consisting of M and Y; Fx(54-60) is the sequence MGNELTF (SEQ ID NO:2, positions 54-60); Vb(61) is selected from the group consisting of L and E; Fx(62-92) is the sequence DDSICTGTSSGNQVNLTIQGLRAMDTGLYIC (SEQ ID NO:2, positions 62-92); Vb(93) is selected from the group consisting of K and Q; and Fx(94-124) is the sequence VELMYPPPYYLGIGNGTQIYVIDPEPCPDSD (SEQ ID NO:2, positions 94-124); wherein the variant exhibits increased binding to B7-1, B7-2, or both B7-1 and B7-2.

[0015] In another aspect, the invention provides an immunoadhesin comprising a first domain comprising a variant human CTLA4 and a second domain comprising an IgG Fc region, wherein the first domain has the formula: Fx(1-28)-Vb(29)-Fx(30-50)-Vb(51)-Fx(52)-Vb(53)-Fx(54-60)-Vb(61)-Fx(62-92)-Vb(93)-Fx(94-124) [SEQ ID NO:3], wherein Fx(1-28) is the sequence MHVAQPAVVLASSRGIASFVCEYASPGK (positions 1-28 of SEQ ID NO:3); Vb(29) is selected from the group consisting of A and H; Fx(30-50) is the sequence TEVRVTVLRQADSQVTEVCAA (SEQ ID NO:3); NO:3, positions 30-50); Vb(51) is N; Fx(52) is Y; Vb(53) is selected from the group consisting of M and Y; Fx(54-60) is the sequence MGNELTF (SEQ ID NO:3, positions 54-60); Vb(61) is selected from the group consisting of L and E; Fx(62-92) is the sequence DDSICTGTSSGNQVNLTIQGLRAMDTGLYIC (SEQ ID NO:3, positions 62-92); Vb(93) is selected from the group consisting of K and Q; and Fx(94-124) is the sequence VELMYPPPYYLGIGNGTQIYVIDPEPCPDSD (SEQ ID NO:3, positions 94-124); wherein the variant exhibits increased binding to B7-1, B7-2, or both B7-1 and B7-2.

[0016] In a further aspect, the invention provides an immunoadhesin comprising a first domain comprising a variant human CTLA4 and a second domain comprising an IgG Fc region, wherein the first domain has the formula: Fx(1-28)-Vb(29)-Vb(30)-Vb(31)-Fx(32)-Vb(33)-Fx(34)-Vb(35)-Fx(36-48)-Vb(49)-Fx(50)-Vb(51)-Fx(52)-Vb(53) -Fx(54-58)-Vb(59)-Fx(60)-Vb(61)-Fx(62)-Vb(63)-Vb(64)-Fx(65-92)-Vb(93)-Fx(94)-Vb(95)-F x(96)-Vb(97)-Vb(98)-Fx(99-101)-Vb(102)-Vb(103)-Vb(104)-Vb(105)-Vb(106)-Fx(107-124)[SEQ ID NO:4]; wherein Fx(1-28) is the sequence MHVAQPAVVLASSRGIASFVCEYASPGK (positions 1-28 of SEQ ID NO:4); Vb(29) is selected from the group consisting of A, E, F, H, K, N, Q and R; Vb(30) is selected from the group consisting of T, H and V; Vb(31) is selected from the group consisting of E, D, I, M, T and V; Fx(32) is V; Vb(33) is selected from the group consisting of R, E, F, I, L, M, Q, T, W and Y; Fx(34) is V; Vb(35) is selected from the group consisting of T, D, E, F, M, V and Y; Fx(36-48) is the sequence VLRQADSQVTEVC (SEQ ID NO:4). NO:4, positions 36-48); Vb(49) is selected from the group consisting of A, D, E, F, T, W and Y; Fx(50) is A; Vb(51) is selected from the group consisting of T, D, E, H, L, N, Q, R, S and V; Fx(52) is Y; Vb(53) is selected from the group consisting of M, E, F, H, Q, W and Y; Fx(54-58) is the sequence MGNELT (SEQ ID NO:4, positions 54-58); Vb(59) is selected from the group consisting of T, H, I, L, N, Q, V and Y; Fx(60) is F; Vb(61) is selected from the group consisting of L, A, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W and Y; Fx(62) is D; Vb(63) is selected from the group consisting of D and E; Vb(64) is selected from the group consisting of S, K, R and Y; Fx(65-92) is the sequence ICTGTSSGNQVNLTIQGLRAMDTGLYIC (SEQ ID NO:3, positions 65-92); Vb(93) is selected from the group consisting of K, D, E, F, H, N, Q, R, S, T, V, W and Y; Fx(94) is V;Vb(95) is selected from the group consisting of E, D, H, L, Q and Y; Fx(96) is L; Vb(97) is selected from the group consisting of M, D, F, I, N and V; Vb(98) is selected from the group consisting of Y, F and W; Fx(99-101) is the sequence PPP; Vb(102) is selected from the group consisting of Y, F and W; Vb(103) is selected from the group consisting of Y, D, E, F, H, N, Q and W; Vb(104) is selected from the group consisting of L, F, H, M, V and Y; Vb(105) is selected from the group consisting of G, D and E; Vb(106) is selected from the group consisting of I, E and Y; and Fx(107-124) is the sequence GNGTQIYVIDPEPCPDSD (positions 107-124 of SEQ ID NO:4), wherein the variant comprises the same sequence as SEQ ID NO:4. NO: at least one amino acid modification compared to 6 and wherein the variant exhibits increased binding to B7-1, B7-2, or both B7-1 and B7-2. ;

[0017] In a further aspect, the invention provides an immunoadhesin comprising SEQ ID NO:8, wherein the immunoadhesin comprises amino acid modifications compared to SEQ ID NO:6.

[0018] In a further aspect, the invention provides an immunoadhesin comprising a first domain comprising a variant CTLA4 as compared to SEQ ID NO:6 and a second domain comprising an IgG Fc region, wherein the CTLA4 variant comprises amino acid modifications selected from the group consisting of T51N, A29H, M53Y, L61E and K93Q, wherein the variant provides enhanced binding to B7-1, B7-2, or both B7-1 and B7-2.

[0019] In an additional aspect, the invention provides an immunoadhesin comprising a first domain comprising a variant CTLA4 as compared to SEQ ID NO:6 and a second domain comprising an IgG Fc region, wherein the CTLA4 variant comprises an amino acid modification at a position selected from the group consisting of 51, 53, 61 and 93 using the numbering of SEQ ID NO:6, wherein the variant provides enhanced binding to B7-1, B7-2, or both B7-1 and B7-2.

[0020] In one aspect of the invention, the CTLA4-Ig immunoadhesin comprises a native Fc region. Preferred native Fc regions of the invention include, but are not limited to, IgG1, IgG2, IgG3, and IgG4 Fc regions.

[0021] In a preferred aspect of the invention, the CTLA4-Ig immunoadhesin comprises a variant Fc region. In a preferred aspect of the invention, the variant Fc region enhances affinity for the neonatal Fc receptor FcRn. In a most preferred aspect of the invention, the variant Fc region extends the in vivo half-life of CTLA4-Ig. Preferred variants for enhancing FcRn affinity and / or extending in vivo half-life include, but are not limited to, 259I, 307Q, 308F, 311I, 311V, 378V, 378T, 426V, 428L, 434S, 436I, 436V, 250Q, 434A, 252Y, 254T and 256E, wherein the numbering is according to the EU index. The most preferred variants for enhancing FcRn affinity and / or extending in vivo half-life are 428L and 434S, wherein the numbering is according to the EU index.

[0022] The present invention provides isolated nucleic acids encoding novel CTLA4-Ig immunoadhesins described herein. The present invention provides vectors comprising the nucleic acids, optionally operably linked to control sequences. The present invention provides host cells comprising the vectors, and methods for producing and optionally recovering the immunoadhesins.

[0023] The present invention provides novel CTLA4-Ig proteins. The novel CTLA4-Ig proteins can be used in therapeutic products.

[0024] The present invention provides a composition comprising the CTLA4-Ig protein described herein, and a physiologically or pharmaceutically acceptable carrier or diluent.

[0025] The present invention encompasses therapeutic and diagnostic uses of the CTLA4-Ig immunoadhesins disclosed herein. The CTLA4-Ig immunoadhesins of the present invention are preferably used to treat immune-related disorders. In a most preferred embodiment of the present invention, the CTLA4-Ig immunoadhesins described herein are used to treat Crohn's disease, systemic lupus erythematosus (SLE), lupus nephritis, psoriatic arthritis, psoriasis, rheumatoid arthritis, ulcerative colitis, and / or transplant rejection. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 .Amino acid sequences of full-length human CTLA4, the extracellular domain (ECD) of human CTLA4, and the belatacept A29Y / L104E variant form of human CTLA4. The ECD of CTLA4 is highlighted in grey in the full-length CTLA4 sequence. The grey highlights A29Y / L104E substitutions in the belatacept sequence [SEQ ID NO: 5-8].

[0027] Figure 2. Amino acid sequences of exemplary Fc regions. The Fc region herein is defined from position 230 to the C-terminus (230-447) based on the EU numbering scheme. Grey highlights indicate modifications from the native IgG Fc region [SEQ ID NO: 9-15].

[0028] Figure 3 . Amino acid sequences of exemplary linkers. Linker numbering is based on the EU index and includes residues 216-229, where 216 is based on EU numbering, the N-terminus 216E of the four native IgG isotypes. The addition of an N-terminal Q does not change the numbering (i.e., 216E is still 216E). Grey highlights indicate modifications from native IgG linkers [SEQ ID NO: 16-23].

[0029] Figure 4 . Amino acid sequences of exemplary combinations of linkers and Fc regions used in this study. Grey highlights indicate modifications from native IgG constant region sequences [SEQ ID NO: 24-27].

[0030] Figure 5 .Amino acid sequences of selected CTLA4-Ig immunoadhesins investigated in this study [SEQ ID NO:28-30].

[0031] Figure 6 For all single-substitution CTLA4-Ig variants screened, represented by grey triangles, the fold increase (k) relative to abatacept off ). Black squares represent the parental CTLA4-Ig abatacept, and black open circles represent belatacept.

[0032] Figure 7 Compared with abatacept and belatacept, CTLA4-Ig variants have higher CD80 and CD86 K D Figure 1. The CTLA4-Ig variants in this study are represented by gray triangles. Black squares represent the parental CTLA4-Ig abatacept, and black open circles represent belatacept.

[0033] Figure 8 Biacore sensorgrams comparing the binding of the CTLA4-Ig variant HNEQ (A29H / T51N / L61E / K93Q) to abatacept and belatacept on CD86 (upper panel) and CD80 (lower panel).

[0034] Fig. 9 .Amino acid sequences of exemplary variant CTLA4 and variant CTLA4-Ig proteins [SEQ ID NO:31-34].

[0035] Fig.10.T cell suppressive activity of CTLA4-Ig variants. T cells were activated by co-ligation of CD3 using anti-CD3 antibody and B7-2 using recombinant B7-2-Ig. CFSE-labeled T cells were monitored using flow cytometry.

[0036] Fig.11 . Amino acid sequences of exemplary CTLA4-Ig variants with Fc variants that extend in vivo half-life [SEQ ID NO:35-38].

[0037] Fig.12 Biacore sensorgrams of native and Fc variant forms of CTLA4-Ig protein binding to human FcRn at pH 6.0. LS refers to the 428L / 434S variant.

[0038] Fig.13 Graph of the FcRn binding affinities (pH 6.0) of native Fc and variant Fc forms of CTLA4-Ig protein as determined by Biacore. LS refers to the 428L / 434S variant.

[0039] Fig.14 .T cell suppressive activity of CTLA4-Ig variants. T cells were activated by co-ligation of CD3 using anti-CD3 antibody and B7-2 using recombinant B7-2-Ig. CFSE-labeled T cells were monitored using flow cytometry.

[0040] Fig.15 T cell suppressive activity of CTLA4-Ig variants in mixed lymphocyte reactions. T cells were activated with a mixture of allogeneic PBMCs from two sets of experiments (one from donors 2336 and 3070 (upper panel) and one from donors 3070 and 3995 (lower panel). Activation was quantified by measuring IL-2 release by ELISA.

[0041] Fig.16 . In vivo inhibitory activity of variant CTLA4-Ig proteins. The ability of CTLA4-Ig proteins to inhibit the human immune response to tetanus was performed in severe combined immunodeficient (SCID) mice transplanted with human peripheral blood leukocytes (PBL). The figure shows the serum levels of anti-tetanus antibodies (anti-TT IgG) when treated with PBS (PBS+TT), abatacept and variant CTLA4 (NEQ)-Ig (ab) (51N / 61E / 93Q with enhanced affinity for B7-1 and B7-2) after tetanus challenge on day 21 after PBL transplantation. PBS alone (no tetanus) was run as a negative control. DETAILED DESCRIPTION OF THE INVENTION

[0042] Overview

[0043] The present invention relates to novel variant CTLA4-Ig immunoadhesins with improved B7 affinity and enhanced T cell inhibitory activity. Such novel immunoadhesins are beneficial in a variety of applications, as discussed in detail below.

[0044] CTLA4 (cytotoxic T lymphocyte antigen 4), also referred to as CTLA-4, also known as CD152 (cluster of differentiation 152), is a protein that plays an important regulatory role in the immune system. In humans, the CTLA4 protein is encoded by the CTLA4 gene, and its translated amino acid sequence is provided in SEQ ID NO: 1. CTLA4 is a member of the immunoglobulin superfamily and is structurally homologous to a T cell co-stimulatory protein CD28. CTLA4 binds to the co-stimulatory ligands B7-1 and B7-2 on the surface of antigen presenting cells (APCs). CLTA4 inhibits immune responses in two main ways—it competes with CD28 for binding to B7-1 and B7-2 to block co-stimulation, and it also negatively transmits signals to inhibit T cell activation. The region of the CTLA4 protein that is particularly important for the present invention is the extracellular domain (ECD) (SEQ ID NO: 2), which mediates binding to the B7-1 and B7-2 ligands on the APC.

[0045] Due to the critical role of the B7 co-stimulatory pathway in promoting and maintaining immune responses, it is desirable to provide therapeutic agents designed to antagonize this pathway. Accordingly, the present invention provides CTLA4Ig immunoadhesins.

[0046] CTLA4-Ig immunoadhesin

[0047] The present invention provides CTLA4Ig immunoadhesins."Immunoadhesin" refers to a protein in which one or more polypeptides are operably linked to an Fc region. As used herein, immunoadhesin is synonymous with the terms "Fc fusion", "Ig fusion", "receptor Fc fusion", "Ig chimera", and "receptor globulin" (sometimes with dashes), and "TRAP" as used in the prior art (Chamow et al., 1996, Trends Biotechnol 14:52-60; Ashkenazi et al., 1997, Curr Opin Immunol 9:195-200, all incorporated by reference in their entirety). Immunoadhesin combines the Fc region of an immunoglobulin with a fusion partner, which can generally be any protein or small molecule that is specific for a target protein. Thus, an immunoadhesin has two main parts - a target binding portion and an Fc portion. The target binding portion can be specific for virtually any target or target antigen. The Fc portion can bind to one or more Fc receptors or Fc ligands. The fusion partner can be linked to any region of the Fc region, including at the N- or C-terminus, or some residues between the termini. Although virtually any protein or small molecule can be linked to Fc to create an Fc fusion, thereby targeting virtually any target, the immunoadhesins of the present invention include CTLA4 or a variant of CTLA4 as a fusion partner. The fusion of CTLA4 and the Ig Fc region is referred to herein as CTLA4-Ig or CTLA4-Ig protein.

[0048] CTLA4 variants

[0049] The target binding portion or fusion partner of the immunoadhesin of the present invention includes the protein CTLA4. Therefore, the immunoadhesin of the present invention is directed to binding B7-1, B7-2, and any other ligand or receptor known or unknown that is bound by CTLA4. The target binding portion of the present invention may include an amino acid sequence consisting of all, any or part of the human CTLA4 protein (SEQ ID NO: 1). Preferably, the immunoadhesin binding portion includes all or part of the ECD of CTLA4 (SEQ ID NO: 2). As described in the Examples, the immunoadhesin binding is preferably improved to B7-1, B7-2, or both B7-1 and B7-2, and in some cases shows a variant of preferential binding to one or another CTLA4.

[0050] CTLA4 variants include at least one amino acid modification in a native CTLA4 protein, which is typically a human CTLA4 protein depicted in SEQ ID NO: 1. In most cases, since the complete CTLA4 protein is not typically used in the fusion protein of the present invention, the variant is in the extracellular domain. In this embodiment, one or more modifications are made at one or more of the following positions (as numbered in SEQ ID NO: 2): 29, 30, 31, 33, 35, 49, 51, 53, 59, 61, 63, 64, 93, 95, 97, 98, 102, 103, 104, 105, or 106. In some embodiments, the modification is one or more of the following substitutions: A29E, A29F, A29H, A29K, A29N, A29Q, A29R, T30E, T30H, T30R, T30V, E31D, E31I, E31M, E31T, E31V, R33E, R33F, R33I, R33L, R33M, R33Q, R33T, R33W, R33Y, T35D, T35E, T35F, T35V 35M, T35V, T35Y, A49D, A49E, A49F, A49T, A49W, A49Y, T51D, T51E, T51H, T51L, T51N, T51Q, T51R, T51 S, T51V, M53E, M53F, M53H, M53Q, M53W, M53Y, T59H, T59I, T59L, T59N, T59Q, T59V, T59Y, L61A, L61D, L61E, L61F, L61G, L61H, L61I, L61K, L61M, L61N, L61P, L61Q, L61R, L61S, L61T, L61V, L61W, L61Y, D6 3E, S64K, S64R, S64Y, K93D, K93E, K93F, K93H, K93N, K93Q, K93R, K93S, K93T, K93V, K93W, K93Y, E95D , E95H, E95L, E95Q, E95Y, M97D, M97F, M97I, M97N, M97V, Y98F, Y98W, Y102F, Y102W, Y103D, Y103E, Y103F, Y103H, Y103N, Y103Q, Y103W, L104F, L104H, L104M, L104V, L104Y, G105D, G105E, I106E, and I106Y.In some embodiments, particularly useful are those having one or more substitutions selected from A29H, T51N, M53Y, L61E, and K93Q, having A29H / K93Q, A29H / M53Y, A29H / T51N, T51N / K93Q, T51N / M53Y, A29H / L61E / K93Q, A29H / M53Y / K93Q, A29H / M53Y / L61E, A29H / T51N / L61E, M53Y / L61E / Particularly useful combinations of CTLA4 variants include K93Q, T51N / L61E / K93Q, T51N / M53Y / L61E, A29H / M53Y / L61E / K93Q, A29H / T51N / L61E / K93Q, A29H / T51N / M53Y / K93Q, A29H / T51N / M53Y / L61E, T51N / M53Y / L61E / K93Q, and A29H / T51N / M53Y / L61E / K93Q.

[0051] For all listings of positions and substitutions herein, it is understood that any and all possible combinations of individual substitutions may be made, and any individual position or substitution may be independently included or excluded from a possible list. Typically, variants of the invention typically have 1, 2, 3, 4, or 5 amino acid substitutions in the CTLA4 region compared to wild-type or parent CTLA4 (or Fc region), and in some cases more substitutions may be used as long as the desired function is retained. Similarly, the Fc domain may also have substitutions in this manner, as described below.

[0052] As described elsewhere, CTLA4 variants generally retain or enhance binding to one or more CTLA4 ligands, such as enhanced binding to B7-1 and / or B7-2.

[0053] Fc domain

[0054] The Fc portion of the immunoadhesin of the present invention includes the Fc region of an antibody or a portion of the Fc region.Antibodies are immunoglobulins that bind to specific antigens.In most mammals, including humans and mice, antibodies are constructed from paired heavy and light chain polypeptides.The light and heavy chain variable regions show significant sequence diversity between antibodies and are responsible for binding to the target antigen.Each chain is composed of a single immunoglobulin (Ig) domain, so the general term immunoglobulin is used for such proteins.

[0055] Conventional natural antibody structural units usually include tetramers. Each tetramer usually includes two pairs of identical polypeptide chains, each pair having a "light chain" (usually with a molecular weight of about 25kDa) and a "heavy chain" (usually with a molecular weight of about 50-70kDa). Human light chains are divided into κ and λ light chains. Heavy chains are divided into μ, δ, γ, α or ε, and the isotypes of antibodies are respectively specified as IgM, IgD, IgG, IgA and IgE. IgG has multiple subclasses, including but not limited to IgG1, IgG2, IgG3 and IgG4. IgM has multiple subclasses, including but not limited to IgM1 and IgM2. IgA has multiple subclasses, including but not limited to IgA1 and IgA2. Therefore, "isotype" used herein refers to any of the types and subclasses of immunoglobulins defined by the chemical and antigenic characteristics of their constant regions. The known human immunoglobulin isotypes are IgGl, IgG2, IgG3, IgG4, IgAl, IgA2, IgMl, IgM2, IgD and IgE. The distinguishing features between these antibody types are their constant regions, although subtle differences may exist in the variable regions.

[0056] Each light chain and heavy chain is composed of two different regions called variable region and constant region. IgG heavy chain includes four immunoglobulin domains connected from N- to C-terminus in the order of VH-CH1-CH2-CH3, which refer to heavy chain variable domain, heavy chain constant domain 1, heavy chain constant domain 2 and heavy chain constant domain 3 (also referred to as VH-Cγ1-Cγ2-Cγ3, which refer to heavy chain variable domain, constant γ1 domain, constant γ2 domain and constant γ3 domain respectively). IgG light chain includes two immunoglobulin domains connected from N- to C-terminus in the order of VL-CL, which refer to light chain variable domain and light chain constant domain respectively. Constant region shows less sequence diversity and is responsible for initiating important biochemical events by binding to a large number of natural proteins. The structure of the natural biological form of the antibody, including variable region and constant region, is referred to as "full-length antibody" herein. In most mammals, including humans and mice, full-length antibodies of the IgG isotype are tetramers composed of two identical pairs of two immunoglobulin chains, each pair having one light chain and one heavy chain, each light chain comprising the immunoglobulin domains VL and CL, and each heavy chain comprising the immunoglobulin domains VH, Cγ1, Cγ2 and Cγ3.

[0057] The variable region, usually the amino-terminal portion of an antibody, contains the antigen-binding determinants of the molecule, thereby determining the antibody's specificity for its target antigen. The variable region is so named because it is the most distinct in sequence from other antibodies of the same type.

[0058] The carboxyl terminal portion of each chain defines the constant region primarily responsible for effector function. In the immunoglobulins of the IgG subclass, there are multiple immunoglobulin domains in the heavy chain, referred to as the heavy chain constant (CH) region. In the context of IgG antibodies, each IgG isotype has three CH regions. Therefore, the "CH" domain in the IgG context is as follows: "CH1" refers to positions 118-220 according to the EU index in Kabat. "CH2" refers to positions 237-340 according to the EU index in Kabat, and "CH3" refers to positions 341-447 according to the EU index in Kabat.

[0059] Another important region of the heavy chain is the hinge region. "Hinge" or "hinge region" or "antibody hinge region" or "immunoglobulin hinge region" herein refers to a flexible polypeptide comprising the amino acids between the first and second constant domains of an antibody. Structurally, the IgG CH1 domain ends at EU position 220, and the IgG CH2 domain begins at residue EU position 237. Thus for IgG, the antibody hinge is defined herein as including positions 221 (D221 in IgG1) to 236 (G236 in IgG1), wherein numbering is according to the EU index in Kabat. In some embodiments, such as in the context of an Fc region, a lower hinge is included, and "lower hinge" generally refers to positions 226 or 230 to 236.

[0060] For all constant region positions discussed in the present invention, numbering is according to the EU index in Kabat (Kabat et al., 1991, Sequences of Proteins of Immunological Interest, 5th Edition, United States Public Health Service, National Institutes of Health, Bethesda, incorporated by reference in its entirety). Those skilled in the art of antibodies will understand that these conventions consist of non-continuous numbering in specific regions of immunoglobulin sequences, enabling standardized reference to conserved positions in the immunoglobulin family. Therefore, the position of any given immunoglobulin determined by the EU index will not necessarily correspond to its continuous sequence.

[0061] The immunoadhesin of the present invention is a protein that is a fusion of CTLA4 and the Fc region of an antibody. "Fc" or "Fc region" used herein refers to a polypeptide comprising a constant region of an antibody excluding the first constant region immunoglobulin domain, and in some cases a partial hinge. Therefore, Fc refers to the flexible hinge at the N-terminus of the last two constant region immunoglobulin domains of IgA, IgD and IgG, the last three constant region immunoglobulin domains of IgE and IgM, and these domains. For IgA and IgM, Fc may include a J chain. For IgG, Fc includes immunoglobulin domains Cγ2 and Cγ3 (Cγ2 and Cγ3) and a lower hinge region between Cγ1 (Cγ1) and Cγ2 (Cγ2). Although the boundaries of the Fc region may vary, the human IgG heavy chain Fc region is defined as including residues 230 to the C-terminus, wherein numbering is based on the EU numbering scheme. Fc may refer to this region of separation or this region in the Fc polypeptide background. As used herein, "Fc polypeptide" refers to a polypeptide comprising all or part of the Fc region. Fc polypeptides include antibodies, Fc fusions, isolated Fc and Fc fragments.

[0062] The Fc region of an antibody interacts with a variety of Fc receptors and ligands, conferring an important set of functional capabilities, known as effector functions. For the Fc region of IgG, Fc includes Ig domains Cγ2 and Cγ3 and an N-terminal hinge that guides Cγ2. An important family of Fc receptors of the IgG class is the Fcγ receptor (FcγR). These receptors mediate communication between antibodies and the cell arm of the immune system (Raghavan et al., 1996, Annu Rev Cell Dev Biol 12: 181-220; Ravetch et al., 2001, Annu Rev Immunol 19: 275-290, all hereby incorporated by reference in their entirety). In humans, this family of proteins includes FcγRI (CD64), including isoforms FcγRIa, FcγRIb, and FcγRIc; FcγRII (CD32), including isoforms FcγRIIa (including allotypes H131 and R131), FcγRIIb (including FcγRIIb-1 and FcγRIIb-2), and FcγRIIc; and FcγRIII (CD16), including isoforms FcγRIIIa (including allotypes V158 and F158) and FcγRIIIb (including allotypes FcγRIIIb-NA1 and FcγRIIIb-NA2) (Jefferis et al., 2002, Immunol Lett 82:57-65, hereby incorporated by reference in its entirety). These receptors usually have an extracellular domain that mediates binding to Fc, a transmembrane region, and an intracellular domain that can mediate some signal transduction events in the cell. These receptors are expressed in a variety of immune cells including monocytes, macrophages, neutrophils, dendritic cells, eosinophils, mast cells, platelets, B cells, large granular lymphocytes, Langerhans cells, natural killer (NK) cells and γδT cells. The formation of Fc / FcγR complexes recruits these effector cells to the position of binding antigens, usually leading to signal transduction events in cells and important secondary immune responses such as release of inflammatory mediators, B cell activation, endocytosis, phagocytosis and cytotoxic attacks. The ability to mediate cytotoxic and phagocytic effector functions is an effective mechanism by which antibodies destroy targeted cells. The cell-mediated reaction in which nonspecific cytotoxic cells express FcγRs that recognize bound antibody on target cells and subsequently result in lysis of the target cell is called antibody-dependent cell-mediated cytotoxicity (ADCC) (Raghavan et al., 1996, Annu Rev Cell Dev Biol 12:181-220; Ghetie et al., 2000, Annu Rev Immunol 18:739-766; Ravetch et al., 2001, Annu Rev Immunol 19:275-290, all of which are hereby incorporated by reference in their entireties).The cell-mediated reaction in which nonspecific cytotoxic cells express FcγRs that recognize bound antibodies on target cells and subsequently result in phagocytosis of the target cells is called antibody-dependent cell-mediated phagocytosis (ADCP).

[0063] Different IgG subclasses have different affinities for FcγR, with IgG1 and IgG3 generally binding to receptors better than IgG2 and IgG4 (Jefferis et al., 2002, Immunol Lett 82: 57-65, hereby incorporated by reference in its entirety). FcγR binds to the IgG Fc region with different affinities. The extracellular domains of FcγRIIIa and FcγRIIIb are 96% identical, but FcγRIIIb does not have an intracellular signal transduction domain. Moreover, although FcγRI, FcγRIIa / c and FcγRIIIa are positive regulators of immune complex-triggered activation, characterized by having an intracellular domain with an immunoreceptor tyrosine-based activation motif (ITAM), FcγRIIb has an immunoreceptor tyrosine-based inhibition motif (ITIM) and is therefore inhibitory. Therefore, the former is called an activating receptor and FcγRIIb is called an inhibitory receptor. Despite these differences in affinity and activity, all FcγRs bind to the same region on Fc, N-terminal to the Cγ2 domain and preceding the hinge.

[0064] Overlapping but different positions on Fc serve as the interface of complement protein C1q. In the same way that Fc / FcγR binds to mediate ADCC, Fc / C1q binds to mediate complement-dependent cytotoxicity (CDC). The position between Cγ2 and Cγ3 domains on Fc mediates interaction with the neo-receptor FcRn, which binds to recycle endocytosed antibodies from endosomes back to the bloodstream (Raghavan et al., 1996, Annu Rev Cell Dev Biol 12: 181-220; Ghetie et al., 2000, Annu Rev Immunol 18: 739-766, all hereby incorporated by reference in their entirety). This process, together with the prevention of renal filtration due to the large size of the full-length molecule, results in a favorable antibody serum half-life that varies from one week to three weeks. The binding of Fc to FcRn also plays a key role in antibody transport. The binding position of FcRn on Fc is also the position where bacterial proteins A and G bind. Tight binding by these proteins is often used as a means of purifying antibodies by employing Protein A or Protein G affinity chromatography during protein purification. The fidelity of these regions, complement and FcRn / Protein A binding regions, is important for both the clinical characterization of antibodies and their development.

[0065] A key feature of the Fc region is the conserved N-linked glycosylation that occurs at N297. This carbohydrate, or oligosaccharide as it is sometimes called, plays a key structural and functional role for the antibody and is one of the main reasons that antibodies must be produced using mammalian expression systems. This modification is required for efficient binding of the Fc to FcγRs and C1q, and alterations in the carbohydrate composition of N297 or its elimination affect binding to these proteins.

[0066] The immunoglobulin of the embodiment disclosed herein can be encoded by the immunoglobulin gene belonging to any antibody type. In certain embodiments, the immunoglobulin disclosed herein includes an antibody belonging to the IgG class, including the sequence of IgG1, IgG2, IgG3 or IgG4. In alternative embodiments, the immunoglobulin disclosed herein includes the sequence of an antibody belonging to IgA (including subclass IgA1 and IgA2), IgD, IgE, IgG or IgM class. The immunoglobulin disclosed herein may include more than one protein chain, for example, may be a monomer or oligomer, including an antibody or Fc fusion of a homo-oligomer or a hetero-oligomer.

[0067] The immunoglobulins disclosed herein may be encoded by genes from substantially any organism, such as mammals (including but not limited to humans), rodents (including but not limited to mice and rats), lagomorphs (including but not limited to rabbits and hares), camelids (including but not limited to camels, alpacas, and dromedaries), and non-human primates, including but not limited to prosimians, platyrrhines (New World monkeys), macaques (Old World monkeys), and the Hominoidea, including gibbons and small and great apes. In the most preferred embodiments, the immunoglobulins disclosed herein may be substantially human.

[0068] As is well known in the art, there are immunoglobulin polymorphisms in the human population. Gm polymorphism is determined by IGHG1, IGHG2 and IGHG3 genes, which have alleles encoding G1m, G2m and G3m allotypes of markers called human IgG1, IgG2 and IgG3 molecules (Gm allotypes have not been found on the γ4 chain). Markers can be divided into "allotypes" and "isoallotypes". These are distinguished on different serological bases, depending on the strong sequence homology between isotypes. Allotypes are antigenic determinants specified by the allelic form of Ig genes. Allotypes represent slight differences in the heavy chain or light chain amino acid sequences of different individuals. Even if a single amino acid difference can lead to an allotype determinant, although multiple amino acid substitutions have occurred in many cases. Allotypes are sequence differences between alleles of subclasses, and antisera are used to identify only allele differences. A heteroallele is an allele within an isotype that produces an epitope shared with a non-polymorphic homologous region of one or more other isotypes, so the antiserum will react with both the related allotype and the related homologous isotype (Clark, 1997, IgG effector mechanisms, Chem Immunol. 65:88-110; Gorman & Clark, 1990, Semin Immunol 2(6):457-66, both of which are hereby incorporated by reference in their entirety).

[0069] The allelic forms of human immunoglobulins have been well characterized (WHO Review of the notation for the allotypic and related markers of human immunoglobins. J Immunogen 1976, 3: 357-362; WHO Review of the notation for the allotypic and related markers of human immunoglobins. 1976, Eur. J. Immunol. 6, 599-601; Loghem E van, 1986, Allotypic markers, Monogr Allergy 19: 40-51, all of which are hereby incorporated by reference in their entirety). In addition, other polymorphisms have been characterized (Kim et al., 2001, J. Mol. Evol. 54: 1-9, hereby incorporated by reference in their entirety). Currently, 18 Gm allotypes are known: G1m (1, 2, 3, 17) or G1m (a, x, f, z), G2m (23) or G2m (n), G3m (5, 6, 10, 11, 13, 14, 15, 16, 21, 24, 26, 27, 28) or G3m (b1, c3, b5, b0, b3, b4, s, t, g1, c5, u, v, g5) (Lefranc, et al., The human IgG subclasses: molecular analysis of structure, function and regulation. Pergamon, Oxford, pp. 43-78 (1990); Lefranc, G. et al., 1979, Hum. Genet.: 50, 199-211, all of which are hereby incorporated by reference in their entirety). Allotypes inherited in a fixed combination are called Gm unit types. The immunoglobulins disclosed herein can be encoded by substantially any allotype, heteroallotype, or haplotype of any immunoglobulin gene.

[0070] The CTLA4 protein can be connected to the Fc region via a linker. The term "linker" is used to refer to a polypeptide comprising two or more amino acid residues bound by a peptide bond and used to connect one or more antigen binding moieties. Such linker polypeptides are well known in the art (see, for example, Holliger, P., et al. (1993) Proc. Natl. Acad. Sci. USA 90: 6444-6448; Poljak, RJ, et al. (1994) Structure 2: 1121-1123). In some embodiments described herein, a variety of linkers can be used to covalently link the Fc region to the fusion partner. "Linkers" herein are also referred to as "linker sequences", "spacers", "linking sequences" or their grammatical synonyms. Homobifunctional or heterobifunctional linkers are well known in the art (see, 1994 Pierce Chemical Company catalog, technical section on cross-linkers, pages 155-200, incorporated by reference in their entirety). A large number of strategies can be used to covalently link molecules together. These include but are not limited to polypeptide bonding between the N- and C-terminal ends of a protein or protein domain, bonding via a disulfide bond, and bonding via a chemical cross-linking agent. In one aspect of this embodiment, a joint is a peptide bond produced by recombinant technology or peptide synthesis. The joint peptide may mainly include the following amino acid residues: Gly, Ser, Ala, or Thr. The joint peptide should have a length suitable for connecting two molecules, and its connection mode is to take the correct conformation relative to each other to maintain the desired activity. In one embodiment, the joint length is from about 1 to 50 amino acids, preferably about 1 to 30 amino acids in length. In one embodiment, a joint with a length of 1 to 20 amino acids can be used. Useful joints include glycine-serine polymers, including, for example, (GS) n, (GSGGS) n [SEQ ID NO: 39], (GGGGS) n [SEQ ID NO: 40], and (GGGS) n [SEQ ID NO: 41], wherein n is an integer of at least 1, glycine-alanine polymers, alanine-serine polymers, and other flexible joints. Alternatively, a variety of non-proteinaceous polymers, including but not limited to polyethylene glycol (PEG), polypropylene glycol, polyoxyalkylenes, or copolymers of polyethylene glycol and polypropylene glycol, can be used as linkers, ie, can be used as linkers.

[0071] Preferred linkers of the present invention include sequences from the hinge region of an antibody. Hinge region sequences from any antibody isotype can be used, including, for example, hinge sequences from IgG1, IgG2, IgG3 and / or IgG4. The linker sequence may also include any sequence of any length of the CL / CH1 domain but not all residues of the CL / CH1 domain; for example, the first 5-12 amino acid residues of the CL / CH1 domain. The linker may be derived from an immunoglobulin heavy chain of any isotype, including, for example, Cγ1, Cγ2, Cγ3, Cγ4, Cα1, Cα2, Cδ, Cε and Cμ. The linker may be derived from an immunoglobulin light chain, such as Cκ or Cλ. The linker sequence may also be derived from other proteins such as Ig-like proteins (e.g., TCR, FcR, KIR), hinge region derived sequences, and other native sequences from other proteins.

[0072] Amino acid modifications in the CTLA4-Ig immunoadhesin

[0073] The CTLA4-Ig immunoadhesins disclosed herein may include variant CTLA4, variant Fc regions, or both variant CTLA4 and variant Fc regions. Variants include one or more amino acid modifications relative to the parent CTLA4-Ig protein, wherein the amino acid modifications provide one or more optimized features. "Modification" herein refers to changes in the physical, chemical or sequence characteristics of a protein, polypeptide, antibody or CTLA4-Ig immunoadhesin. "Amino acid" and "amino acid identity" as used herein refer to one of the 20 naturally occurring amino acids or any non-natural analogs that can be present at a particular designated position. Thus, "amino acid" as used herein refers to both naturally occurring and synthetic amino acids. For example, for the purposes of the present invention, homophenylalanine, citrulline and norleucine are considered amino acids. "Amino acid" also includes imine residues such as proline and hydroxyproline. The side chain can be in the (R) or (S) configuration. In a preferred embodiment, the amino acid is in the (S) or L- configuration. If a non-naturally occurring side chain is used, a non-amino acid substituent can be used, for example to prevent or delay in vivo degradation. Amino acid modifications can be amino acid substitutions, insertions, and / or deletions in the polypeptide sequence. As used herein, "amino acid substitution" or "substitution" refers to the replacement of one amino acid with another amino acid at a specific position in a parent polypeptide sequence. As used herein, "amino acid insertion" or "insertion" refers to the addition of an amino acid at a specific position in a parent polypeptide sequence. As used herein, "amino acid deletion" or "deletion" refers to the removal of an amino acid at a specific position in a parent polypeptide sequence.

[0074] The variants disclosed herein differ from their parents in terms of amino acid sequence due to at least one amino acid modification. "Parent polypeptide", "parent protein", "precursor polypeptide" or "precursor protein" used herein refers to an unmodified polypeptide that is subsequently modified to produce a variant. The parent polypeptide may be a naturally occurring polypeptide, i.e., a WT or native protein, or a variant or engineered form of a naturally occurring polypeptide. The parent polypeptide may refer to the polypeptide itself, a composition comprising the parent polypeptide, or an amino acid sequence encoding it. "Wild type", "WT" or "native" herein refers to an amino acid sequence or nucleotide sequence found in nature, including allelic variants. WT proteins including, for example, WT CTLA4 or WT Fc region proteins have an amino acid sequence or nucleotide sequence that has not been intentionally modified. The CTLA4-Ig immunoadhesin disclosed herein may have more than one amino acid modification compared to the parent, such as about 1 to 50 amino acid modifications compared to the parent, such as about 1 to 10 amino acid modifications, about 1 to about 5 amino acid modifications, etc. The sequence of the variant is substantially homologous to the sequence of the parent polypeptide. For example, the variant sequence herein will have about 80% homology with the parent sequence, such as at least about 90% homology, at least about 95% homology, at least about 98% homology, at least about 99% homology, etc. Modifications disclosed herein also include glycoform modifications. Modifications can be performed genetically using molecular biology, or can be performed enzymatically or chemically.

[0075] Variants disclosed herein are defined according to the amino acid modifications that make them up. Thus, for example, the substitution T51N in CTLA4 refers to a CTLA4 variant in which the threonine at position 51 is replaced by asparagine. As another example, the substitution N434S in the Fc region refers to an Fc variant in which the asparagine at position 434 is replaced by serine. Similarly, M428L / N434S defines an Fc variant having substitutions M428L and N434S relative to the parent Fc polypeptide. The identity of the WT amino acid may not be specified, in which case the aforementioned variant is referred to as 428L / 434S. It should be noted that the order in which the substitutions are provided is random, i.e., for example, 428L / 434S is the same Fc variant as 434S / 428L. For modifications in CTLA4, the position numbering herein is the sequential numbering of the CTLA4 extracellular region provided in SEQ ID NO:6. The positions of antibody constant regions and Fc regions discussed herein are numbered according to the EU index or EU numbering scheme (Kabat et al., 1991, Sequences of Proteins of Immunological Interest, 5th Edition, United States Public Health Service, National Institutes of Health, Bethesda, hereby incorporated by reference in its entirety). The EU index or the EU index or EU numbering scheme in Kabat refers to the numbering of EU antibodies (Edelman et al., 1969, Proc Natl Acad Sci USA 63:78-85, hereby incorporated by reference in its entirety).

[0076] The purpose of the variant herein is to provide one or more optimized features, usually by changing the affinity to the target ligand or Fc receptor. Affinity can be enhanced or reduced relative to the parent protein. As used herein, "greater affinity" or "improved affinity" or "enhanced affinity" or "better affinity" than the parent polypeptide refers to that the variant binds to the ligand or receptor with a significantly higher association equilibrium constant (KA or Ka) or a lower dissociation equilibrium constant (KD or Kd) than the parent polypeptide under the same conditions, and the same conditions, for example, the amount of the variant and the parent polypeptide in the binding test is substantially the same.

[0077] For example, a CTLA4 variant with improved B7-2 binding affinity can exhibit about a 1.2, 1.5, 2, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100-fold or more improvement in B7-2 binding affinity compared to a parent CTLA4 polypeptide, wherein B7-2 binding affinity is determined by one of skill in the art using, for example, the binding methods disclosed herein, including but not limited to, Biacore. TM Sure.

[0078] Accordingly, as used herein, "reduced affinity" compared to a parent polypeptide means that the variant binds to a ligand or receptor with a significantly lower KA or higher KD than the parent polypeptide. Greater or reduced affinity can also be defined relative to the absolute level of affinity.

[0079] The immunoadhesins herein preferably include variant CTLA4. CTLA4 variants may improve binding to B7-1, B7-2, or both B7-1 and B7-2. CTLA4 variants may improve selective binding to B7-2 relative to B7-1. That is, the variants may enhance the affinity of CTLA4 to B7-2, but reduce the affinity to B7-1, do not affect the affinity to B7-1, or improve the affinity to B7-2 less than the affinity to B7-1. Alternatively, the variants may improve selective binding to B7-1 relative to B7-2.

[0080] The immunoadhesins herein preferably include Fc variants. The Fc variants disclosed herein can be optimized to improve or reduce binding to Fc receptors or Fc ligands. "Fc receptors" or "Fc ligands" used herein refer to molecules, preferably polypeptides, that form Fc-ligand complexes from the Fc region of binding antibodies of any organism. Fc ligands include, but are not limited to, FcγRs, FcγRs, FcγRs, FcRn, C1q, C3, mannan binding lectins, mannose receptors, Staphylococcal protein A, Streptococcal protein G, and viral FcγRs. Fc ligands also include Fc receptor homologs (FcRH), which are Fc receptor families homologous to FcγRs. Fc ligands may include undiscovered molecules that bind to Fc.

[0081] In a preferred embodiment, the CTLA4-Ig immunoadhesin disclosed herein incorporates an Fc variant that improves FcRn binding. Such variants can enhance the in vivo pharmacokinetic characteristics of the CTLA4-Ig immunoadhesin. Preferred variants that increase FcRn binding and / or improve pharmacokinetic characteristics include, but are not limited to, substitutions at positions 259, 308, 428, and 434, including, but not limited to, for example, 259I, 308F, 428L, 428M, 434S, 434H, 434F, 434Y, and 434M (USSN 12 / 341,769, filed December 22, 2008, entitled "Fc Variants with Altered Binding to FcRn", incorporated by reference in its entirety). Other variants that increase Fc binding to FcRn include, but are not limited to: 250E, 250Q, 428L, 428F, 250Q / 428L (Hinton et al., 2004, J. Biol. Chem. 279(8):6213-6216, Hinton et al. 2006 Journal of Immunology 176:346-356), 256A, 272A, 286A, 305A, 307A, 307Q, 311A, 312A, 376A, 378Q, 380A, 382A, 434A (Shields et al., Journal of Biological Chemistry, 2001, 276(9):6591-6604, incorporated by reference in its entirety), 252F, 252T, 252Y, 252W, 254T, 256S, 256R, 256Q, 256E, 256D, 256T, 309P, 311S, 433R, 433S, 433I, 433P, 433Q, 434H, 434F, 434Y, 252Y / 254T / 256E, 433K / 434F / 436H, 308T / 309P / 311S (Dall Acqua et al., Journal of Immunology, 2002, 169:5171-5180, Dall'Acqua et al., 2006, Journal of Biological Chemistry 281:23514-23524, incorporated by reference in its entirety). Other modifications for modulating FcRn binding are described in Yeung et al., 2010, J Immunol, 182:7663-7671.

[0082] Other Fc modifications used in the present invention include variants that reduce or remove the binding to FcγRs and / or complement proteins, thereby reducing or removing Fc-mediated effector functions such as ADCC, ADCP and CDC. Such variants are also referred to herein as "knockout variants" or "KO variants". Variants that reduce the binding to FcγRs and complement can be used to reduce unwanted interactions mediated by the Fc region and to adjust the selectivity of CTLA4-Ig immunoadhesin. Preferred knockout variants are described in US 2008-0242845 A1 published on 10 / 2 / 2008, entitled "Fc Variants with Optimized Properties", which is clearly incorporated herein by reference. Preferred modifications include but are not limited to substitutions, insertions and deletions at positions 234, 235, 236, 237, 267, 269, 325 and 328, wherein numbering is according to the EU index. Preferred substitutions include, but are not limited to, 234G, 235G, 236R, 237K, 267R, 269R, 325L, and 328R, wherein numbering is according to the EU index. Preferred variants include 236R / 328R. Variants can be used in the context of any IgG isotype or IgG isotype Fc region, including but not limited to human IgG1, IgG2, IgG3, and / or IgG4. Preferred IgG Fc regions for reducing FcγR and complement binding and reducing Fc-mediated effector functions are IgG2 and IgG4 Fc regions. Hybrid isotypes can also be useful, such as the hybrid IgG1 / IgG2 isotypes described in USSN 11 / 256,060. Other modifications for reducing FcγR and complement interactions include, but are not limited to, substitutions 297A, 234A, 235A, 237A, 318A, 228P, 236E, 268Q, 309L, 330S, 331S, 220S, 226S, 229S, 238S, 233P, and 234V, and removal of glycosylation at position 297 by mutation or enzymatic means or by production in organisms that do not glycosylate proteins, such as bacteria. These and other modifications are reviewed in Strohl, 2009, Current Opinion in Biotechnology 20: 685-691, incorporated by reference in its entirety.

[0083] Improved Fc modifications for FcγRs and / or complement binding can also be used in the CTLA4-Ig immunoadhesins herein. Such Fc variants can enhance Fc-mediated effector functions such as ADCC, ADCP and / or CDC. Preferred modifications for improving FcγR and complement binding are described in US 2006-0024298 A1 published on 2 / 2 / 2006 and US 2006-0235208 A1 published on 10 / 19 / 2006, which are expressly incorporated herein by reference. Preferred modifications include substitutions at positions selected from the group consisting of 236, 239, 268, 324 and 332, wherein numbering is according to the EU index. Preferred substitutions include, but are not limited to, 236A, 239D, 239E, 268D, 267E, 268E, 268F, 324T, 332D and 332E. Preferred variants include, but are not limited to, 239D / 332E, 236A / 332E, 236A / 239D / 332E, 268F / 324T, 267E / 268F, 267E / 324T, and 267E / 268F / 324T. Other modifications for enhancing FcγR and complement interactions include, but are not limited to, substitutions 298A, 333A, 334A, 326A, 247I, 339D, 339Q, 280H, 290S, 298D, 298V, 243L, 292P, 300L, 396L, 305I, and 396L. These and other modifications are reviewed in Strohl, 2009, supra.

[0084] In one embodiment, the CTLA4-Ig immunoadhesins disclosed herein may incorporate Fc variants that enhance affinity for the inhibitory receptor FcγRIIb. Such variants may provide the CTLA4-Ig immunoadhesins herein with enhanced affinity for FcγRIIb. +In one embodiment, the Fc variant provides an affinity for FcγRIIb selectively enhanced relative to one or more activating receptors. Modifications that change the binding of FcγRIIb are described in USSN 12 / 156,183, filed May 30, 2008, entitled "Methods and Compositions for Inhibiting CD32b Expressing Cells", which is expressly incorporated herein by reference. Specifically, the Fc variants that improve the binding of FcγRIIb may include one or more modifications at a position selected from the group consisting of 234, 235, 236, 237, 239, 266, 267, 268, 325, 326, 327, 328, and 332 according to the EU index. Preferred substitutions for enhancing affinity of FcγRIIb include, but are not limited to, 234D, 234E, 234W, 235D, 235F, 235R, 235Y, 236D, 236N, 237D, 237N, 239D, 239E, 266M, 267D, 267E, 268D, 268E, 327D, 327E, 328F, 328W, 328Y, and 332E. More preferably, substitutions include, but are not limited to, 235Y, 236D, 239D, 266M, 267E, 268D, 268E, 328F, 328W, and 328Y. Preferred Fc variants for enhanced binding to FcγRIIb include, but are not limited to, 235Y / 267E, 236D / 267E, 239D / 268D, 239D / 267E, 267E / 268D, 267E / 268E, and 267E / 328F.

[0085] The CTLA4-Ig immunoadhesins described herein can be incorporated into any IgG isotype or IgG isotype Fc region background, including but not limited to Fc modifications in human IgG1, IgG2, IgG3, and / or IgG4. IgG isotypes can be selected such as to change FcγR- and / or complement-mediated effector functions. Hybrid IgG isotypes can also be useful. For example, USSN 11 / 256,060 describes a large number of hybrid IgG1 / IgG2 constant regions that can be used in specific inventions. In some embodiments of the present invention, the CTLA4-Ig immunoadhesin may include a means of isotype modification, that is, the amino acid type in the parent IgG is modified to replace the IgG. For example, an IgG1 / IgG3 hybrid variant can be constructed by substitution means, substituting the IgG1 position in the CH2 and / or CH3 region with an amino acid from IgG3 at a position where the two isotypes are distinguished. Thus, hybrid variant IgG antibodies comprising one or more substitution means such as 274Q, 276K, 300F, 339T, 356E, 358M, 384S, 392N, 397M, 422I, 435R and 436F can be constructed. In other embodiments of the present invention, IgG1 / IgG2 hybrid variants can be constructed by substitution means, substituting IgG2 positions in the CH2 and / or CH3 regions with amino acids from IgG1 at positions where the two isotypes differ. Thus, hybrid variant IgG antibodies comprising one or more substitution means such as one or more of the following amino acid substitutions can be constructed: 233E, 234L, 235L, -236G (referring to the insertion of glycine at position 236), and 327A.

[0086] As will be appreciated by those skilled in the art, the disclosure of individual and combined variants in the Fc region can be independently and optionally combined with any CTLA4 variant disclosed herein. That is, as described herein, CTLA4 variants are selected and / or combined individually and optionally in any combination in the disclosed variant group. Similarly, the above list of suitable Fc domain variants can be combined individually and optionally in any manner, not only in the Fc region but also in combination with any CTLA4 variant. That is, CTLA4 variants including a large number of variants such as A29H / T51N / L61E / K93Q can be selected, and these variants can be combined with Fc domain variants such as 239D / 332E and / or 428L / 434S. Thus, the disclosure of a "list" of possible individual variants refers to any and all possible combinations in the list and combinations with lists of other variants for the same purpose or other purposes.

[0087] Glycoform modification

[0088] The antibody Fc region contains carbohydrates at a conserved position in the constant region of the heavy chain. Each antibody isotype has a unique carbohydrate structure of multiple N-connections. In addition to the carbohydrates connected to the heavy chain, up to 30% of human IgG has a glycosylated Fab region. IgG has a single N-connected biantennary carbohydrate at Asn297 of the CH2 domain. For IgG from serum or produced in vitro in hybridomas or engineered cells, IgG is mixed with carbohydrates connected to Asn297. For human IgG, the core oligosaccharide is usually composed of GlcNAc2Man3GlcNAc, with different numbers of external residues.

[0089] The carbohydrate portion of the immunoadhesins disclosed herein will be described with reference to the common nomenclature used to describe oligosaccharides. A review of carbohydrate chemistry using this nomenclature is found in Hubbard et al. 1981, Ann. Rev. Biochem. 50:555-583. This nomenclature includes, for example, Man for mannose; GlcNAc for 2-N-acetylglucosamine; Gal for galactose; Fuc for fucose; and Glc for glucose. Sialic acid is described with abbreviated symbols, NeuNAc for 5-N-acetylneuraminic acid, and NeuNGc for 5-hydroxyacetoxyneuraminic acid.

[0090] The term "glycosylation" refers to the attachment of oligosaccharides (a carbohydrate containing two or more monosaccharides linked together, e.g., two to about twelve monosaccharides linked together) to a glycoprotein. Oligosaccharide side chains are typically attached to the backbone of a glycoprotein via N- or O-bonding. The oligosaccharides of the immunoadhesins disclosed herein are typically attached to the CH2 domain of the Fc region as N-attached oligosaccharides. "N-attached glycosylation" refers to the attachment of carbohydrate moieties to asparagine residues in the glycoprotein chain. Those skilled in the art will recognize that, for example, each of the CH2 domains of mouse IgG1, IgG2a, IgG2b, and IgG3 and human IgG1, IgG2, IgG3, IgG4, IgA, and IgD has a single site for N-attached glycosylation at residue 297.

[0091] For the purposes of this article, "mature core carbohydrate structure" refers to the processed core carbohydrate structure attached to the Fc region, which is usually composed of the following carbohydrate structure typical of biantennary oligosaccharides, GlcNAc(fucose)-GlcNAc-Man-(Man-GlcNAc)2. The mature core carbohydrate structure is attached to the Fc region of the glycoprotein, usually via N-bonding to Asn297 of the CH2 domain of the Fc region. "Bisecting GlcNAc" is a GlcNAc residue attached to the α1,4 mannose of the mature core carbohydrate structure. The bisecting GlcNAc can be enzymatically attached to the mature core carbohydrate structure by α(1,4)-N-acetylglucosaminyltransferase III (GnTIII). CHO cells do not normally express GnTIII (Stanley et al., 1984, J. Biol. Chem. 261: 13370-13378), but can be engineered to do so (Umana et al., 1999, Nature Biotech. 17: 176-180).

[0092] Described herein are CTLA4-Ig immunoadhesins including modified glycoforms or engineered glycoforms. As used herein, "modified glycoforms" or "engineered glycoforms" refer to carbohydrate compositions covalently attached to a protein, such as an antibody, wherein the carbohydrate composition is chemically different from the parent protein. Engineered glycoforms can be used for a variety of purposes, including but not limited to enhancing or reducing FcγR-mediated effector functions. In one embodiment, the CTLA4-Ig immunoadhesins disclosed herein are modified to control the level of fucosylated and / or bisecting oligosaccharides covalently attached to the Fc region.

[0093] A variety of methods for generating modified glycoforms are known in the art (Umana et al., 1999, Nat Biotechnol 17: 176-180; Davies et al., 2001, Biotechnol Bioeng 74: 288-294; Shields et al., 2002, J Biol Chem 277: 26733-26740; Shinkawa et al., 2003, J Biol Chem 278: 3466-3473; USSN 12 / 434,533; all expressly incorporated by reference). These techniques control the level of fucosylated and / or bisecting oligosaccharides covalently attached to the Fc region, for example by expressing the IgG in a variety of engineered or other organisms or cell lines (e.g., Lec-13 CHO cells or rat hybridoma YB2 / 0 cells), by modulating enzymes involved in the glycosylation pathway (e.g., FUT8 [α1,6-fucosyltransferase] and / or β1-4-N-acetylglucosaminyltransferase III [GnTIII]), by modifying carbohydrates after the IgG has been expressed, or by expressing the antibody in the presence of a fucose analog that acts as an enzyme inhibitor. Other methods for modifying glycoforms of the CTLA4-Ig immunoadhesins disclosed herein include the use of glycoengineered strains of yeast (Li et al., 2006, Nature Biotechnology 24(2):210-215), moss (Nechansky et al., 2007, Mol Immunjol 44(7):1826-8), and plants (Cox et al., 2006, Nat Biotechnol 24(12):1591-7). The use of a specific method for producing modified glycoforms is not intended to limit the embodiments to that method. Rather, the embodiments disclosed herein encompass CTLA4-Ig immunoadhesins having modified glycoforms, regardless of how they are produced.

[0094] In one embodiment, the CTLA4-Ig immunoadhesin disclosed herein is glycoengineered to change the level of sialylation. Higher levels of sialylated Fc glucans in the CTLA4-Ig immunoadhesin G molecule can adversely affect functionality (Scallon et al., 2007, Mol Immunol. 44 (7): 1524-34), and differences in Fc sialylation levels can lead to altered anti-inflammatory activity (Kaneko et al., 2006, Science 313: 670-673). Since antibodies may acquire anti-inflammatory characteristics due to sialylation of the Fc core polysaccharide, glycoengineering the CTLA4-Ig immunoadhesin disclosed herein may be advantageous for greater or reduced Fc sialic acid content.

[0095] Engineered glycoforms generally refer to different carbohydrates or oligosaccharides; so for example, an immunoglobulin may include an engineered glycoform. Alternatively, an engineered glycoform may refer to a CTLA4-Ig immunoadhesin that includes different carbohydrates or oligosaccharides. In one embodiment, the composition disclosed herein includes a glycosylated CTLA4-Ig immunoadhesin with an Fc region, wherein about 51-100% of the glycosylated antibodies, such as 80-100%, 90-100%, 95-100%, etc. of the antibodies in the composition include a mature core carbohydrate structure lacking fucose. In another embodiment, the antibodies in the composition include a mature core carbohydrate structure lacking fucose and additionally include at least one amino acid modification in the Fc region. In an alternative embodiment, the composition includes a glycosylated CTLA4-Ig immunoadhesin with an Fc region, wherein about 51-100% of the glycosylated antibodies, 80-100% or 90-100% of the antibodies in the composition include a mature core carbohydrate structure lacking sialic acid. In another embodiment, the antibody in the composition includes a mature core carbohydrate structure lacking sialic acid and additionally includes at least one amino acid modification in the Fc region. In yet another embodiment, the composition includes a glycosylated CTLA4-Ig immunoadhesin with an Fc region, wherein about 51-100% of the glycosylated antibodies, 80-100% or 90-100% of the antibodies in the composition include a mature core carbohydrate structure comprising sialic acid. In another embodiment, the antibody in the composition includes a mature core carbohydrate structure comprising sialic acid and additionally includes at least one amino acid modification in the Fc region. In another embodiment, the combination of engineered glycoforms and amino acid modifications provides the antibody with optimal Fc receptor binding characteristics.

[0096] Other Modifications

[0097] The CTLA4-Ig immunoadhesins disclosed herein may include one or more modifications that provide optimized characteristics. The modifications may be amino acid modifications, or may be modifications that are performed enzymatically or chemically. Such modifications may provide some improvements in the CTLA4-Ig immunoadhesins, such as enhancements in their stability, solubility, function, or clinical use. Various improvements that may be made by combining the CTLA4-Ig immunoadhesins disclosed herein with additional modifications are disclosed herein.

[0098] In one embodiment, modifications are made to improve the biophysical characteristics of the CTLA4-Ig immunoadhesins disclosed herein, including but not limited to stability, solubility, and oligomeric state. Modifications may include, for example, substitutions that provide more favorable intramolecular interactions in the CTLA4-Ig immunoadhesins, such as to provide greater stability, or to replace exposed non-polar amino acids with polar amino acids for higher solubility. Other modifications to the CTLA4-Ig immunoadhesins disclosed herein include those that enable specific formation of homodimeric or homopolymeric molecules. Such modifications include but are not limited to engineered disulfides, and chemical modifications or aggregation methods.

[0099] In further embodiments, the CTLA4-Ig immunoadhesins disclosed herein include modifications that remove proteolytic degradation sites. These may include, for example, protease sites that reduce productivity and protease sites that degrade the administered protein in vivo. In one embodiment, additional modifications are made to remove covalent degradation sites such as deamidation (i.e., deamidation of glutaminyl and asparaginyl residues to corresponding glutamyl and aspartyl residues), oxidation, and proteolytic degradation sites. Particularly useful deamidation sites for removal are those with enhanced deamidation tendencies, including but not limited to asparaginyl and glutaminyl residues, followed by glutamic acid (NG and QG motifs, respectively). In this case, substitution of any residue can significantly reduce the tendency to deamidation. Common oxidation sites include methionine and cysteine ​​residues. Other covalent modifications that can be introduced or removed include hydroxylation of proline and lysine, phosphorylation of the hydroxyl group of seryl or threonyl residues, methylation of the "-amino" of lysine, arginine and histidine side chains, acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group. Additional modifications may also include, but are not limited to, post-translational modifications such as N-linked or O-linked glycosylation and phosphorylation.

[0100] Modifications may include those that improve the expression and / or purification yield from a host or host cell commonly used to produce biomass. These include, but are not limited to, a variety of mammalian cell lines (e.g., CHO), yeast cell lines, bacterial cell lines, and plants. Additional modifications include modifications that remove or reduce the ability of the heavy chain to form interchain disulfide bonds. Additional modifications include modifications that remove or reduce the ability of the heavy chain to form intrachain disulfide bonds.

[0101] The CTLA4-Ig immunoadhesins disclosed herein may include modifications including the use of unnatural amino acids incorporated using methods including, but not limited to, those described in Liu & Schultz, 2010, Annu Rev Biochem 79: 413-444, expressly incorporated herein by reference. In some embodiments, these modifications enable manipulation of the various functional, biophysical, immunological, or manufacturing characteristics discussed above. In other embodiments, these modifications enable additional chemical modifications for other purposes.

[0102] Other modifications are contemplated herein. For example, the CTLA4-Ig immunoadhesin may be linked to one of a variety of non-proteinaceous polymers, such as polyethylene glycol (PEG), polypropylene glycol, polyoxyalkylenes, or copolymers of polyethylene glycol and polypropylene glycol. Additional amino acid modifications may be made to enable specific or non-specific chemical or post-translational modification of the CTLA4-Ig immunoadhesin. Such modifications include, but are not limited to, pegylation and glycosylation. Specific substitutions that may be used to enable pegylation include, but are not limited to, the introduction of new cysteine ​​residues or non-natural amino acids, so that efficient and specific coupling chemical reactions may be used to attach PEG or other polymeric moieties. The introduction of specific glycosylation sites may be achieved by introducing new NXT / S sequences into the CTLA4-Ig immunoadhesins disclosed herein.

[0103] Modifications that reduce immunogenicity may include modifications that reduce the binding of processed peptides derived from the parent sequence to MHC proteins. For example, amino acid modifications will be engineered so that there is no or minimal amount of immune epitopes that are predicted to bind with high affinity to any common MHC allele. Many methods for identifying MHC binding epitopes in protein sequences are known in the art and can be used to evaluate epitopes in antibodies disclosed herein.

[0104] Covalent modifications are included in the scope of the CTLA4-Ig immunoadhesins disclosed herein, and are usually, but not always, performed post-translationally. For example, by reacting specific amino acid residues with an organic derivatizing agent capable of reacting with a selected side chain or N- or C-terminal residue, many types of covalent modifications can be introduced into the molecule. In some embodiments, the covalent modification of the immunoglobulins disclosed herein includes the addition of one or more labels. The term "labeling group" refers to any detectable label. In some embodiments, the labeling group is coupled to the CTLA4-Ig immunoadhesin via a spacer arm of various lengths to reduce possible steric hindrance. A variety of methods for labeling proteins are known in the art and can be used to produce the CTLA4-Ig immunoadhesin disclosed herein.

[0105] In one embodiment, the CTLA4-Ig immunoadhesin disclosed herein is a "fusion protein", sometimes referred to herein as a "conjugate". The fusion partner or conjugation partner can be proteinaceous or non-proteinaceous; the latter is generally produced using functional groups on the CTLA4-Ig immunoadhesin and on the conjugation partner. Conjugates and fusion partners can be any molecule, including small molecule chemical compounds and polypeptides. For example, a variety of conjugates and methods are described in Trail et al., 1999, Curr. Opin. Immunol. 11: 584-588, which is incorporated by reference in its entirety. Possible conjugation partners include, but are not limited to, cytokines, cytotoxic agents, toxins, radioisotopes, chemotherapeutic agents, anti-angiogenic agents, tyrosine kinase inhibitors, and other therapeutically active agents. In some embodiments, the conjugation partner can be considered more as a load, that is, the purpose of the conjugate is to target the delivery of the conjugation partner to the cells targeted by the CTLA4-Ig immunoadhesin, such as cancer cells or immune cells. Thus, for example, conjugation of a toxin to a CTLA4-Ig immunoadhesin targets delivery of the toxin to cells expressing the target antigen. One skilled in the art will appreciate that, in practice, the concepts and definitions of fusion and conjugate overlap. The designation of fusion or conjugate is not meant to limit it to any specific embodiment disclosed herein. Rather, these terms are used loosely to convey the broad concept that any CTLA4-Ig immunoadhesin disclosed herein may be genetically, chemically or otherwise linked to one or more polypeptides or molecules to provide some desired property.

[0106] Production of CTLA4-Ig immunoadhesin

[0107] Also disclosed herein are methods for producing and experimentally testing CTLA4-Ig immunoadhesins. The disclosed methods are not meant to limit the embodiments to any particular operational application or principle. Rather, the methods provided are meant to generally describe that one or more CTLA4-Ig immunoadhesins can be produced and experimentally tested to obtain CTLA4-Ig immunoadhesins. General methods for antibody and protein molecular biology, expression, purification and screening are described in Antibody Engineering, Kontermann & Dubel, Springer, Heidelberg, 2001; and Hayhurst & Georgiou, 2001, Curr Opin Chem Biol 5: 683-689; Maynard & Georgiou, 2000, Annu Rev Biomed Eng 2: 339-76.

[0108] In one embodiment disclosed herein, a nucleic acid encoding a CTLA4-Ig immunoadhesin is produced, which can then be cloned into a host cell, expressed and tested if desired. In this way, nucleic acids encoding each protein sequence can be prepared, especially DNA. These practices are performed using well-known protocols. For example, a variety of methods that can be used to produce the CTLA4-Ig immunoadhesin disclosed herein are described in Molecular Cloning-A Laboratory Manual, 3rd Edition. (Maniatis, Cold Spring Harbor Laboratory Press, New York, 2001) and Current Protocols in Molecular Biology (John Wiley & Sons), all of which are incorporated by reference in their entirety. There are a variety of techniques that can be used to effectively produce DNA encoding the CTLA4-Ig immunoadhesin disclosed herein. Such methods include, but are not limited to, gene assembly methods, PCR-based methods and methods using PCR variations, methods based on ligase chain reaction, mixed oligonucleotide methods, such as those used in synthetic shuffling, trial and error amplification methods and methods using oligonucleotides with random mutations, classical site-directed mutagenesis methods, cassette mutagenesis, and other amplification and gene synthesis methods. As is known in the art, there are a variety of commercially available kits and methods for gene assembly, mutagenesis, vector subcloning, and the like, and such commercial products can be used to generate nucleic acids encoding CTLA4-Ig immunoadhesins.

[0109] The CTLA4-Ig immunoadhesin proteins disclosed herein can be produced by culturing a host cell transformed with a nucleic acid, such as an expression vector, comprising a nucleic acid encoding a CTLA4-Ig immunoadhesin under conditions suitable for inducing or causing expression of the protein. Suitable conditions for expression will vary with the choice of expression vector and host cell, and are readily determined by those skilled in the art through routine experimentation. A wide range of appropriate host cells can be used, including, but not limited to, mammalian cells, bacteria, insect cells, yeast, and plant cells. For example, a variety of cell lines that can be used to produce the CTLA4-Ig immunoadhesins disclosed herein are described in the SEQ ID NO: 1, available from the American Type Culture Collection. Cell line catalog.

[0110] In one embodiment, the CTLA4-Ig immunoadhesin is expressed in a mammalian expression system, including a system in which a virus such as a retrovirus or adenovirus is used to introduce an expression construct into a mammalian cell. Any mammalian cell can be used, such as human, mouse, rat, hamster and primate cells. Suitable cells also include known research cells, including but not limited to Jurkat T cells, NIH3T3, CHO, BHK, COS, HEK293, PER C.6, HeLa, Sp2 / 0, NS0 cells and variants thereof. In an optional embodiment, the library protein is expressed in bacterial cells. Bacterial expression systems are well known in the art, including Escherichia coli (E. coli), Bacillus subtilis, Streptococcus cremoris and Streptococcus lividans. In an alternative embodiment, the CTLA4-Ig immunoadhesin is produced in insect cells (such as Sf21 / Sf9, Trichoplusia ni Bti-Tn5b1-4) or yeast cells (such as S. cerevisiae, Pichia, etc.). In an alternative embodiment, a cell-free translation system is used to express the CTLA4-Ig immunoadhesin in vitro. In vitro translation systems derived from prokaryotic cells (such as E. coli) and eukaryotic cells (such as wheat germ, rabbit reticulocytes) are available and can be selected based on the expression level and functional properties of the target protein. For example, those skilled in the art will appreciate that in vitro translation is required for certain display technologies, such as ribosome display. In addition, CTLA4-Ig immunoadhesin can be produced by chemical synthesis methods. There are also transgenic expression systems for animals (such as cow, sheep or goat milk, embryonated chicken eggs, whole insect larvae, etc.) and plants (such as corn, tobacco, duckweed, etc.).

[0111] Nucleic acids encoding the CTLA4-Ig immunoadhesins disclosed herein can be incorporated into expression vectors to express proteins. Many expression vectors can be used for protein expression. Expression vectors can include self-replicating extrachromosomal vectors or vectors that integrate into the host genome. Expression vectors compatible with the host cell type are constructed. Therefore, expression vectors that can be used to produce the CTLA4-Ig immunoadhesins disclosed herein include, but are not limited to, those that enable protein expression in mammalian cells, bacteria, insect cells, yeast, and in vitro systems. It is well known in the art that a variety of expression vectors that can be used to express the CTLA4-Ig immunoadhesins disclosed herein can be obtained commercially or otherwise.

[0112] Expression vectors typically contain proteins operably linked to control or regulatory sequences, selection markers, any fusion partners and / or additional elements. "Operably linked" herein refers to a nucleic acid being placed in a functional relationship with another nucleic acid sequence. In general, these expression vectors include transcriptional and translational regulatory nucleic acids operably linked to nucleic acids encoding CTLA4-Ig immunoadhesin, and are generally suitable for host cells used to express the protein. In general, transcriptional and translational regulatory sequences may include promoter sequences, ribosome binding sites, transcriptional start and stop sequences, translational start and stop sequences, and enhancer or activator sequences. It is also well known in the art that expression vectors typically contain selection genes or markers to allow selection of transformed host cells containing the expression vector. Selection genes are well known in the art and vary with the host cell used.

[0113] The CTLA4-Ig immunoadhesin may be operably linked to a fusion partner to enable targeting, purification, screening, display, etc. of the expressed protein. The fusion partner may be linked to the CTLA4-Ig immunoadhesin sequence via a linker sequence. The linker sequence typically contains a small number of amino acids, generally less than 10, although longer linkers may also be used. In general, the selected linker sequence should be flexible and resistant to degradation. Those skilled in the art will appreciate that any of a wide range of sequences may be used as a linker. For example, a commonly used linker sequence contains the amino acid sequence GGGGS [SEQ ID NO: 40]. The fusion partner may be a targeting or signal sequence that directs the CTLA4-Ig immunoadhesin and any associated fusion partner to a desired cell site or extracellular medium. It is well known in the art that certain signal sequences can target proteins for secretion into the culture medium or into the periplasmic space between the inner and outer membranes of the cell. The fusion partner may also be a sequence encoding a peptide or protein that enables purification and / or screening. Such fusion partners include, but are not limited to, polyhistidine tags (His tags) (e.g., H6 and H10 or other tags used in immobilized metal affinity chromatography (IMAC) systems (e.g., Ni+2 affinity columns), GST fusions, MBP fusions, Strep tags, BSP biotinylated target sequences of the bacterial enzyme BirA, and epitope tags targeted by antibodies (e.g., c-myc tags, flag tags, etc.). One skilled in the art will appreciate that such tags can be used for purification, screening, or both. For example, a CTLA4-Ig immunoadhesin can be purified using a His tag by immobilizing it on a Ni+2 affinity column, and then after purification, the same His tag can be used to immobilize the antibody on a Ni+2 coated plate for ELISA or other binding assays (as described below). Fusion partners can make it possible to screen CTLA4-Ig immunoadhesins using selection methods (see below). Fusion partners that can be used for a variety of selection methods are well known in the art.

[0114] In one embodiment, the CTLA4-Ig immunoadhesin is purified or isolated after expression. The protein can be isolated or purified in a variety of ways known to those skilled in the art. Purification can be particularly useful in the present invention for separating heterodimeric heavy chain species from homodimeric heavy chain species, as described herein. Standard purification methods include chromatographic techniques, including ion exchange, hydrophobic interaction, affinity, size or gel filtration, and reverse phase, performed at atmospheric pressure or high pressure using systems such as FPLC and HPLC. Purification methods also include electrophoresis, isoelectric focusing, immunology, precipitation, dialysis, and chromatofocusing techniques. Ultrafiltration and diafiltration techniques are also useful in combination with protein concentration. It is well known in the art that many natural proteins bind to Fc and antibodies, and these proteins can be used to purify the CTLA4-Ig immunoadhesin disclosed herein. For example, bacterial proteins A and G bind to the Fc region. Similarly, bacterial protein L binds to the Fab region of certain antibodies, of course, just like the target antigen of the antibody. Purification can usually be performed by a specific fusion partner. For example, if a GST fusion is used, the CTLA4-Ig immunoadhesin can be purified using glutathione resin, if a His tag is used, Ni+2 affinity chromatography can be used, or if a flag tag is used, an immobilized anti-flag antibody can be used. For general guidance on suitable purification techniques, see, for example, Protein Purification: Principles and Practice, 3rd edition, Scopes, Springer-Verlag, NY, 1994, which is incorporated by reference in its entirety. The required degree of purification will vary depending on the screening or use of the CTLA4-Ig immunoadhesin. In some cases, no purification is required. For example, in one embodiment, if the CTLA4-Ig immunoadhesin is secreted, it can be screened directly from the culture medium. It is well known in the art that some selection methods do not involve protein purification.

[0115] In vitro experiments

[0116] CTLA4-Ig immunoadhesins can be experimentally tested using a variety of in vitro methods, including but not limited to those using binding assays, cell-based assays, and selection techniques. Automation and high-throughput screening techniques can be used in screening protocols. Screening can employ the use of fusion partners or markers. The use of fusion partners has been discussed above. "Labeled" herein refers to the CTLA4-Ig immunoadhesins disclosed herein having one or more elements, isotopes, or chemical compounds attached thereto that enable detection in screening. In general, markers are divided into three categories: a) immune markers, which can be epitopes incorporated as fusion partners that are recognized by antibodies, b) isotope labels, which can be radioactive or heavy isotopes, and c) small molecule labels, which can include fluorescent dyes and colorimetric dyes, or molecules such as biotin that enable other labeling methods. Labels can be incorporated into any position of the compound and can be incorporated in vitro or in vivo during protein expression.

[0117] In one embodiment, the functional and / or biophysical properties of the CTLA4-Ig immunoadhesin are screened in an in vitro assay. In vitro assays can give a wide dynamic range for screening for properties of interest. Particularly relevant to the present invention, the ability of the CTLA4-Ig immunoadhesin to one or more antigens can be tested. The properties that can be screened include, but are not limited to, stability, solubility, and affinity for Fc ligands, such as FcγRs. Multiple properties can be screened simultaneously or separately. Depending on the needs of the assay, the protein can be purified or unpurified. In one embodiment, the screening is a qualitative or quantitative binding assay for the binding of CTLA4-Ig immunoadhesin to proteins or non-protein molecules that are known or believed to bind to CTLA4-Ig immunoadhesin. In one embodiment, the screening is a binding assay for measuring binding to a target antigen. In an optional embodiment, the screening is an assay for the binding of CTLA4-Ig immunoadhesin to Fc ligands, including but not limited to the FcγR family, the neoreceptor FcRn, the complement protein C1q, and bacterial proteins A and G. The Fc ligand can be from any organism. In one embodiment, the Fc ligand is from human, mouse, rat, rabbit and / or monkey. Binding assays can be performed using a variety of methods known in the art, including but not limited to FRET (fluorescence resonance energy transfer) and BRET (bioluminescence resonance energy transfer) based assays, AlphaScreen TM (amplified luminescence proximity assay), scintillation proximity assay, ELTSA (enzyme-linked immunosorbent assay), SPR (surface plasmon resonance, also known as ), isothermal titration calorimetry, differential scanning calorimetry, gel electrophoresis, and chromatography including gel filtration. These and other methods may utilize certain fusion partners or markers of the CTLA4-Ig immunoadhesin. Testing may employ a variety of detection methods, including but not limited to chromogenic, fluorescent, luminescent, or isotopic labels.

[0118] The biophysical properties of CTLA4-Ig immunoadhesins, such as stability and solubility, can be tested using a variety of methods known in the art. Protein stability can be determined by measuring the thermodynamic equilibrium between the folded and unfolded states. For example, the CTLA4-Ig immunoadhesins disclosed herein can be unfolded using chemical denaturants, heating or pH, and the transition can be monitored using methods including, but not limited to, circular dichroism, fluorescence spectroscopy, absorption spectroscopy, NMR spectroscopy, calorimetry, and proteolysis. Those skilled in the art will appreciate that these and other techniques can also be used to monitor the kinetic parameters of the folding and unfolding transitions. The solubility and overall structural integrity of the CTLA4-Ig immunoadhesins can be quantitatively or qualitatively determined using a number of methods known in the art. Methods that can be used to characterize the biophysical properties of the CTLA4-Ig immunoadhesins disclosed herein include gel electrophoresis, isoelectric focusing, capillary electrophoresis, chromatography such as size exclusion chromatography, ion exchange chromatography and reversed phase high performance liquid chromatography, peptide mapping, oligosaccharide mapping, mass spectrometry, ultraviolet absorption spectroscopy, fluorescence spectroscopy, circular dichroism, isothermal titration calorimetry, differential scanning calorimetry, analytical ultracentrifugation, dynamic light scattering, proteolysis and cross-linking, turbidity measurement, filter retardation assays, immunoassays, fluorescent dye binding assays, protein staining assays, microscopy, and detection of aggregates by ELISA or other binding assays. Structural analysis using X-ray crystallography and NMR spectroscopy can also be used. In one embodiment, stability and / or solubility can be measured by determining the amount of protein dissolved after a specified period of time. In this assay, the protein may or may not be exposed to certain extreme conditions, such as high temperature, low pH, or the presence of a denaturant. Because function generally requires stable, soluble, and / or properly folded / structured proteins, the aforementioned functional and binding assays also provide methods for performing such measurements. For example, a solution containing a CTLA4-Ig immunoadhesin can be assayed for its ability to bind a target antigen, then exposed to elevated temperature for one or more defined periods of time, and then assayed again for binding to the antigen. Because unfolded and aggregated protein is not expected to bind antigen, the amount of activity retained provides a measure of the stability and solubility of the CTLA4-Ig immunoadhesin.

[0119] In one embodiment, the CTLA4-Ig immunoadhesin can be tested using one or more cell-based or in vitro assays. For such assays, purified or unpurified CTLA4-Ig immunoadhesin is typically added exogenously so that the cells are exposed to the CTLA4-Ig immunoadhesin described herein. These assays are typically, but not always, based on the biology of the ability of the CTLA4-Ig immunoadhesin to bind to the target antigen and mediate certain biochemical events, such as effector functions like cell lysis, phagocytosis, ligand / receptor binding inhibition, inhibition of growth and / or proliferation, inhibition of calcium release and / or signal transduction, apoptosis, etc. Such assays often include monitoring the response of cells to the CTLA4-Ig immunoadhesin, such as cell survival, cell death, cell phagocytosis, cell lysis, changes in cell morphology, or transcriptional activation such as cellular expression of a natural gene or reporter gene. For example, such assays can measure the ability of the CTLA4-Ig immunoadhesin to induce cell killing, such as ADCC, ADCP, and CDC. Assays that measure cell killing mediated by antigen co-engagement are particularly relevant to the present invention. For some assays, it may be necessary to add additional cells or components other than target cells, such as serum complement or effector cells such as peripheral blood mononuclear cells (PBMC), NK cells, macrophages, T cells, etc. Such additional cells can be from any organism, such as humans, mice, rats, rabbits and monkeys. Cross-linked or monomeric antibodies can cause apoptosis of certain cell lines expressing the target antigen of the antibody, or they can mediate the attack on the target cell by the immune cells added to the assay. Methods for monitoring cell death or viability are well known in the art, including the use of dyes, fluorophores, immunochemistry, cytochemistry and radioactive agents. For example, caspase assays or annexin fluorescent conjugates may be able to measure apoptosis, and the uptake or release of radioactive substrates (such as chromium-51 release assays) or metabolic reduction of fluorescent dyes such as alamar blue may be able to monitor cell growth, proliferation or activation. In one embodiment, a cytotoxicity assay based on DELFIA EuTDA (PerkinElmer, MA) is used. Alternatively, target cells that die or are damaged can be monitored by measuring the release of one or more natural intracellular proteins such as lactate dehydrogenase. Transcriptional activation can also be used as a method for determining function in cell-based assays. In this case, the response can be monitored by measuring natural genes or proteins that may be upregulated or downregulated, such as the release of certain interleukins, or the results can be read out by luciferase or GFP-reporter constructs. Cell-based assays can also include measurements of morphological changes in cell responses to the presence of CTLA4-Ig immunoadhesin. The cell type used for the above-mentioned assay can be prokaryotic or eukaryotic, and a variety of cell lines known in the art can be used. Alternatively, cells transformed or transfected with nucleic acids encoding CTLA4-Ig immunoadhesin are used for cell-based screening.

[0120] In vivo experiments

[0121] The biological properties of the CTLA4-Ig immunoadhesins disclosed herein can be characterized in cell, tissue, and whole organism experiments.

[0122] As shown herein, in general, the binding of the variant CTLA4 domains of the immunoadhesins of the present invention and the related affinity tests are performed using the binding tests outlined in the Examples. As described above, when the KA of the variant polypeptide is significantly higher relative to the parent polypeptide or the KD of the variant polypeptide is significantly lower relative to the parent polypeptide, the affinity can be described as being enhanced. When expressed in terms of a ratio, for example, KA (variant polypeptide) / KA (parent polypeptide) or KD (parent polypeptide) / KD (variant polypeptide), for example, when one and / or two of these ratios are about 1.2, 1.5, 2.0, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 50, 100, 250, 500, 1000 or more, a significant increase in affinity is demonstrated.

[0123] As is known in the art, drugs are often tested in animals, including but not limited to mice, rats, rabbits, dogs, cats, pigs, and monkeys, to measure the efficacy of the drug for treating a disease or disease model, or to measure the pharmacokinetics, toxicity, and other properties of the drug. The animal may be referred to as a disease model. As for the CTLA4-Ig immunoadhesins disclosed herein, there are particular challenges in using animal models to assess the potential for efficacy of candidate polypeptides in humans—this is due, at least in part, to the fact that the Fc domain of the CTLA4-Ig immunoadhesin, which has a particular effect on the affinity of human Fc receptors, may not have a similar affinity effect on orthologous animal receptors. These problems can be further exacerbated by the inevitable uncertainty associated with the correct assignment of true orthologs (Mechetina et al., 2002, Immunogenetics, 54:463-468, incorporated by reference in its entirety), and the fact that some orthologs simply do not exist in animals. Therapeutics are often tested in mice, including but not limited to nude mice, Rag-deficient mice, SCID mice, xenograft mice, and transgenic mice (including knock-ins and knock-outs). The therapeutic CTLA4-Ig immunoadhesins herein can be tested in mouse strains NZB, NOD, BXSB, MRL / lpr, K / BxN, and transgenic types (including knock-ins and knock-outs). Such mice are capable of developing a variety of autoimmune disorders that resemble human organ-specific, systemic autoimmune or inflammatory disease pathologies such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). For example, the CTLA4-Ig immunoadhesins disclosed herein that are intended for use in autoimmune diseases can be tested in such mouse models by treating mice to determine the ability of the CTLA4-Ig immunoadhesins to reduce or inhibit the development of disease pathology. Due to the incompatibility of the mouse and human Fcγ receptor systems, an alternative approach is to use a SCID mouse model, in which immunodeficient mice are transplanted with human PBL or PBMC (huPBL-SCID, huPBMC-SCID), providing a semi-functional human immune system with human effector cells and Fc receptors. Other organisms, such as mammals, can also be used for testing. For example, because of the genetic similarity between monkeys and humans, they can be suitable therapeutic models and therefore can be used to test the efficacy, toxicity, pharmacokinetics or other properties of the CTLA4-Ig immunoadhesins disclosed herein. For approval as a drug, the CTLA4-Ig immunoadhesins disclosed herein must ultimately be tested in humans, so these experiments are certainly contemplated. Therefore, the CTLA4-Ig immunoadhesins disclosed herein can be tested in humans to determine their therapeutic efficacy, toxicity, pharmacokinetics and / or other clinical properties.

[0124] In some embodiments, the CTLA4-Ig immunoadhesins disclosed herein can be evaluated for efficacy in various clinically relevant animal models of human disease. In many cases, relevant models include various transgenic animals for specific antigens and receptors.

[0125] In one embodiment, testing of CTLA4-Ig immunoadhesins may include efficacy studies in primates (such as simian models) to facilitate evaluation of depletion of specific target cells carrying the target antigen. Additional primate models include, but are not limited to, the use of rhesus macaque models to evaluate CTLA4-Ig immunoadhesins in therapeutic studies of autoimmunity, transplantation, and cancer.

[0126] Toxicity studies are conducted to determine drug-related effects that cannot be evaluated in standard pharmacology profiles or that occur only after repeated administration of the agent. Most toxicity tests are conducted in two species (a rodent and a non-rodent) to ensure that no unexpected adverse effects are ignored before the new therapeutic entity is introduced into humans. In general, these models can measure a variety of toxicities, including genotoxicity, chronic toxicity, immunogenicity, reproductive / developmental toxicity, and carcinogenicity. The aforementioned parameters include standard measurements of food consumption, body weight, antibody formation, clinical chemistry, and macroscopic and microscopic examinations of standard organs / tissues (such as cardiotoxicity). Additional measurement parameters are injection site trauma and neutralizing antibody measurements, if any. Traditionally, naked or conjugated monoclonal antibody therapeutics are evaluated for cross-reactivity with normal tissues, immunogenicity / antibody production, conjugates of radiolabeled substances or linker toxicity, and "bystander" toxicity. Nevertheless, such studies may have to be considered individually for specific content and follow the guidance established by ICH S6 (safety studies of biotechnology products also noted above). Likewise, general principles are that the product is adequately characterized and free of impurities / contaminants, that test materials are comparable during development, and that compliance with GLP is maintained.

[0127] The pharmacokinetics (PK) of the CTLA4-Ig immunoadhesins disclosed herein can be studied in a variety of animal systems, the most relevant being non-human primates such as macaques and rhesus monkeys. Single or repeated intravenous / subcutaneous administration of a 6000-fold dose range (0.05-300 mg / kg) can be used to assess the half-life (several days to several weeks) using plasma concentration and clearance. The volume of distribution and systemic absorption levels at steady state can also be measured. Examples of such measurement parameters typically include the maximum measured plasma concentration (Cmax), the time to reach Cmax (Tmax), the area from time 0 to infinity of the plasma concentration-time curve [AUC (0-inf)], and the apparent elimination half-life (T1 / 2). Additional measurement parameters may include compartmental analysis of the concentration-time data obtained after intravenous administration and bioavailability.

[0128] Pharmacodynamic studies may include, but are not limited to, targeting specific cells or blocking signal transduction mechanisms, measuring inhibition of antigen-specific antibodies, etc. The CTLA4-Ig immunoadhesins disclosed herein can target specific effector cell populations and thus direct the drug to induce certain activities to improve efficacy or increase penetration into particularly beneficial physiological compartments. Such pharmacodynamic effects can be demonstrated in animal models or humans.

[0129] Clinical Uses

[0130] The CTLA4-Ig immunoadhesins disclosed herein can be used for a variety of therapeutic purposes. In one embodiment, the CTLA4-Ig immunoadhesins disclosed herein are therapeutic agents, diagnostic agents, or research reagents. The CTLA4-Ig immunoadhesins can be used in compositions that are monoclonal or polyclonal. The CTLA4-Ig immunoadhesins disclosed herein can be used for therapeutic purposes. The CTLA4-Ig immunoadhesins can be administered to a patient to treat a condition.

[0131] For the purposes disclosed herein, "patient" includes humans and other animals, such as other mammals. Thus, the CTLA4-Ig immunoadhesins disclosed herein can be used for both human therapy and veterinary applications. The term "treatment" disclosed herein is intended to include therapeutic treatment of a disease or disorder, as well as preventive or inhibitory measures. Thus, for example, successful administration of a CTLA4-Ig immunoadhesin prior to the onset of the disease results in treatment of the disease. As another example, successful administration of an optimized CTLA4-Ig immunoadhesin after clinical manifestation of the disease to combat the symptoms of the disease constitutes treatment of the disease. "Treatment" also encompasses administration of an optimized CTLA4-Ig immunoadhesin after the onset of the disease to eradicate the disease. Successful administration of an agent after onset and after clinical symptoms have developed, which may eliminate clinical symptoms and may improve the disease, constitutes treatment of the disease. Those "in need of treatment" include mammals already suffering from a disease or disorder, as well as those mammals susceptible to a disease or disorder, including those mammals in which the disease or disorder is to be prevented.

[0132] The CTLA4-Ig immunoadhesins herein are preferably used to treat immune-related disorders or conditions. Immune-related disorders include, but are not limited to, autoimmune diseases, inflammatory disorders, and preventing immune responses associated with rejection of donor tissue bands.

[0133] The CTLA4-Ig immunoadhesins herein can be used to treat autoimmune diseases. "Autoimmune diseases" herein include allogeneic pancreatic islet transplant rejection, alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, autoimmune Addison's disease, antineutrophil cytoplasmic autoantibodies (ANCA), adrenal autoimmune diseases, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune myocarditis, autoimmune neutropenia, autoimmune oophoritis and orchitis, autoimmune thrombocytopenia, autoimmune urticaria, Behcet's disease, bullous pemphigoid, cardiomyopathy, Castleman's syndrome, sprue-dermatitis, chronic fatigue immunodeficiency syndrome, chronic inflammatory demyelinating polyneuropathy, Churg-Schmidt syndrome, and schwann syndrome. trauss syndrome, scarring pemphigoid, CREST syndrome, cold agglutinin disease, Crohn's disease, dermatomyositis, discoid lupus, idiopathic mixed cryoglobulinemia, factor VIII deficiency, fibromyalgia-fibromyositis, glomerulonephritis, Graves' disease, Guillain-Barre syndrome, Goodpasture's syndrome, graft-versus-host disease (GVHD), Hashimoto's thyroiditis, hemophilia A, idiopathic pulmonary fibrosis, idiopathic thrombocytopenic purpura (ITP), IgA neuropathy, IgM polyneuropathy, immune-mediated thrombocytopenia, juvenile arthritis, Kawasaki disease, lichen planus plantus), lupus erthematosis, Meniere's disease, mixed connective tissue disease, multiple sclerosis, type I diabetes mellitus, myasthenia gravis, pemphigus vulgaris, pernicious anemia, polyarteritis nodosa, polychrondritis, polyglandular syndromes, polymyopathy rheumatica, polymyositis and dermatomyositis, essential agammaglobulinemia, primary biliary cirrhosis, psoriasis, psoriatic arthritis, Reynauld's phenomenon, Reiter's syndrome, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, solid organ transplant rejection, stiff-man syndrome, systemic lupus erythematosus, Takayasu's arteritis, temporal arteritis / giant cell arteritis, thrombotic thrombocytopenic purpura, ulcerative colitis, uveitis, vasculitic diseases such as dermatitis herpetiformis vasculitis, white scars, and Wegner's granulomatosis.

[0134] The CTLA4-Ig immunoadhesins herein can be used to treat inflammatory disorders. "Inflammatory disorders" herein include acute respiratory distress syndrome (ARDS), acute septic arthritis, allergic arthritis, juvenile idiopathic arthritis, allergic encephalomyelitis, allergic rhinitis, allergic vasculitis, allergies, asthma, atherosclerosis, chronic inflammation due to chronic bacterial or viral infections, chronic obstructive pulmonary disease (COPD), coronary heart disease, encephalitis, inflammatory bowel disease, inflammatory osteolysis, inflammation associated with acute and delayed hypersensitivity reactions, inflammation associated with tumors, peripheral nerve injury or demyelinating diseases, inflammation associated with tissue trauma such as burns and ischemia, inflammation caused by meningitis, multiple organ injury syndrome, pulmonary fibrosis, sepsis and septic shock, Stevens-Johnson syndrome, undifferentiated joint suppuration, and undifferentiated spondyloarthropathies.

[0135] The CTLA4-Ig immunoadhesins herein can be used to prevent or suppress the immune response of the recipient to reject the donor tissue, cell, graft or organ transplant. Transplant-related diseases or conditions include graft-versus-host disease (GVDH), such as graft-versus-host disease associated with bone marrow transplantation, and immune disorders caused or associated with the rejection of organ, tissue or cell transplants (e.g., tissue or cell allografts or xenografts), including, for example, transplants of skin, muscle, neurons, pancreatic islets, organs, liver parenchymal cells, etc. With respect to donor tissue, cells, grafts or solid organ transplants in the recipient, it is believed that such molecules of the invention disclosed herein (e.g., variant CTLA-4 ECD polypeptides or variant CTLA-4-Ig fusion proteins) can effectively prevent the acute rejection of such transplants in the recipient and / or be used for long-term maintenance therapy to prevent the rejection of such transplants in the recipient (e.g., inhibiting the rejection of insulin-producing islet cell transplants from donors in recipients with diabetes).

[0136] Preferred immune-related disorders that can be treated by the CTLA4-Ig immunoadhesins disclosed herein include Crohn's disease, systemic lupus erythematosus (SLE), lupus nephritis, psoriatic arthritis, psoriasis, rheumatoid arthritis, ulcerative colitis, and transplant rejection, including but not limited to kidney transplantation, liver transplantation, and pancreas transplantation.

[0137] The CTLA4-Ig immunoadhesins herein can be used to treat cancer. "Cancer" and "cancerous" herein refer to or describe a physiological condition in mammals that is generally characterized by unregulated cell growth. Examples of cancer include, but are not limited to, carcinomas, lymphomas, blastomas, sarcomas (including liposarcoma), neuroendocrine tumors, mesotheliomas, schwanomas, meningiomas, adenocarcinomas, melanomas, and leukemias or lymphoid malignancies.

[0138] The CTLA4-Ig immunoadhesins herein can be used to treat infectious diseases. "Infectious diseases" herein include diseases caused by pathogens such as viruses, bacteria, fungi, protozoa and parasites.

[0139] In addition, the CTLA4-Ig immunoadhesins disclosed herein can be used to prevent or treat additional conditions, including but not limited to cardiac conditions such as congestive heart failure (CHF), myocarditis and other myocardial conditions; skin conditions such as rosecea, acne and eczema; bone and dental conditions such as bone loss, osteoporosis, Paget's disease, Langerhans cell histiocytosis, periodontal disease, osteopenia, osteomalacia, monoostotic fibrous dysplasia, multiple fibrous dysplasia, bone metastases, bone pain management, humoral hypercalcemia of malignancy, periodontal remodeling, spinal cord injury and fractures; metabolic conditions such as Gaucher's disease; endocrine conditions such as Cushing's syndrome; and neurological and neurodegenerative conditions such as Alzheimer's disease.

[0140] preparation

[0141] Pharmaceutical compositions in which the CTLA4-Ig immunoadhesins disclosed herein are formulated with one or more therapeutically active agents are contemplated. Preparations of the CTLA4-Ig immunoadhesins disclosed herein are prepared by mixing the CTLA4-Ig immunoadhesins of the desired purity with optional pharmaceutically acceptable carriers, excipients or stabilizers (Remington's Pharmaceutical Sciences, 16th edition, Osol, A. ed., 1980, incorporated by reference in its entirety) and storing in the form of lyophilized formulations or aqueous solutions. Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphates, citrates, acetates, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl alcohol, or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins such as serum albumin, gelatin, or CTL A4-Ig immunoadhesin; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine or lysine; monosaccharides, disaccharides and other sugars, including glucose, mannose or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; sweeteners and other flavoring agents; fillers such as microcrystalline cellulose, lactose, corn and other starches; binders; additives; colorants; salt-forming counterions such as sodium; metal complexes (e.g., Zn-protein complexes); and / or nonionic surfactants such as TWEEN TM 、PLURONICS TMor polyethylene glycol (PEG). In one embodiment, the pharmaceutical composition comprising the CTLA4-Ig immunoadhesin disclosed herein may be present in a water-soluble form, such as in a pharmaceutically acceptable salt, which is intended to include both acid and base addition salts. "Pharmaceutically acceptable acid addition salts" refer to those salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc., and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, etc., which retain the biological effectiveness of the free base and have no adverse biological or other properties. "Pharmaceutically acceptable base addition salts" include those derived from inorganic bases, such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts, etc. Some embodiments include at least one of ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines (including naturally occurring substituted amines), cyclic amines, and basic ion exchange resins (such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine). Preparations for in vivo administration can be sterile. This can be easily achieved by filtering with a sterile filtration membrane or other methods.

[0142] The CTLA4-Ig immunoadhesins disclosed herein can also be formulated into immunoliposomes. Liposomes are small vesicles containing different types of lipids, phospholipids and / or surfactants that can be used to deliver therapeutic agents to mammals. Liposomes containing CTLA4-Ig immunoadhesins can be prepared by methods known in the art. The components of the liposomes are generally arranged in a bilayer structure, similar to the lipid arrangement of biological membranes. Particularly useful liposomes can be produced by reverse phase evaporation using a lipid composition comprising phosphatidylcholine, cholesterol and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded from a filter with a specified pore size to produce liposomes with a desired diameter.

[0143] CTLA4-Ig immunoadhesins and other therapeutic agents may also be encapsulated in microcapsules (microcapsules prepared by methods including, but not limited to, coacervation techniques, interfacial polymerization (e.g., using hydroxymethylcellulose or gelatin microcapsules or poly(methacrylate) microcapsules)), colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules), and macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences, 16th edition, Osol, A., ed., 1980, incorporated by reference in its entirety. Sustained release formulations may be prepared. Suitable examples of sustained release formulations include semipermeable matrices of solid hydrophobic polymers in the form of shaped products, such as films or microcapsules. Examples of sustained release matrices include polyesters, hydrogels (e.g., poly(2-hydroxyethyl-methacrylate) or poly(vinyl alcohol)), polylactides, copolymers of L-glutamic acid and γ-ethyl L-glutamate, non-degradable ethylene-vinyl acetate copolymers, degradable lactic acid-glycolic acid copolymers such as Lupron (which are injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), poly-D-(-)-3-hydroxybutyric acid, and (available from Alkermes), which is a microsphere-based delivery system consisting of the desired bioactive molecule incorporated into a poly-DL-lactide-co-glycolide (PLG) matrix.

[0144] Application

[0145] Administration of a pharmaceutical composition comprising a CTLA4-Ig immunoadhesin disclosed herein, for example in the form of a sterile aqueous solution, can be performed in a variety of ways, including but not limited to oral, subcutaneous, intravenous, intranasal, intraaural, transdermal, topical (such as gels, ointments, lotions, creams, etc.), intraperitoneal, intramuscular, intrapulmonary, vaginal, parenteral, rectal or intraocular. In some cases, such as for the treatment of wounds, inflammation, etc., the CTLA4-Ig immunoadhesin can be directly applied as a solution or spray. It is well known in the art that pharmaceutical compositions can be formulated accordingly depending on the mode of introduction.

[0146] Subcutaneous administration is used in situations where the patient can self-administer the pharmaceutical composition. For subcutaneous administration, many protein therapeutics are not effective enough to allow the formulation of a therapeutically effective dose in the maximum acceptable volume. This problem can be partially solved by using a protein formulation comprising arginine-HCl, histidine, and polysorbate. The CTLA4-Ig immunoadhesin disclosed herein may be more convenient for subcutaneous administration due to, for example, increased efficacy, improved serum half-life, or increased solubility. It is well known in the art that protein therapeutics are often delivered by intravenous infusion or push injection. The CTLA4-Ig immunoadhesin disclosed herein can also be delivered using such a method. For example, 0.9% sodium chloride can be used as an infusion vehicle for administration by intravenous infusion.

[0147] Pulmonary delivery can be achieved using an inhaler or nebulizer and a formulation containing an aerosolizing agent. For example, the Inhalable technology or Inhance available for purchase from Nektar Therapeutics TM Pulmonary Delivery Systems. Furthermore, the CTLA4-Ig immunoadhesins disclosed herein may be amenable to oral delivery.

[0148] In addition, any of a number of delivery systems are known in the art and can be used to administer the CTLA4-Ig immunoadhesins disclosed herein. Examples include, but are not limited to, encapsulation in liposomes, microparticles, microspheres (such as PLA / PGA microspheres), and the like. Alternatively, porous, non-porous, or gelatinous materials, including implants of membranes or fibers, can be used. Sustained release systems can include polymeric materials or matrices such as polyesters, hydrogels, poly(vinyl alcohol), polylactides, copolymers of L-glutamic acid and ethyl L-glutamate, ethylene-vinyl acetate, lactic acid-glycolic acid copolymers such as Lupron. and poly-D-(-)-3-hydroxybutyric acid. It is also possible to administer nucleic acids encoding the CTLA4-Ig immunoadhesins disclosed herein, for example, by retroviral infection, direct injection, or coating with lipids, cell surface receptors, or other transfection agents. In all cases, a controlled release system can be used to release the CTLA4-Ig immunoadhesin at or near the desired site of action.

[0149] Drug administration

[0150] In one embodiment, the dosage and frequency of administration are selected to be effective in treatment or prevention. It is well known in the art that adjustments may have to be made for protein degradation, systemic versus local delivery, and new protease synthesis rates, as well as age, body weight, general health, sex, diet, time of administration, drug interactions, and severity of the condition, and can be determined by those skilled in the art through routine experimentation.

[0151] The concentration of therapeutically active CTLA4-Ig immunoadhesin in the formulation may vary from about 0.1 to 100 weight %. In one embodiment, the concentration of the CTLA4-Ig immunoadhesin is in the range of 0.003-1.0 molar. In order to treat a patient, a therapeutically effective dose of the CTLA4-Ig immunoadhesin disclosed herein may be administered. Herein, "therapeutically effective dose" refers to the dose administered to produce an effect. The exact dose will depend on the purpose of the treatment and will be determined by a person skilled in the art using known techniques. The dosage range may be 0.0001-100 mg / kg body weight or greater, such as 0.1, 1, 10 or 50 mg / kg body weight. In one embodiment, the dosage range is 1-10 mg / kg.

[0152] In some embodiments, only a single dose of CTLA4-Ig immunoadhesin is used. In other embodiments, multiple doses of CTLA4-Ig immunoadhesin are administered. The elapsed time between administrations may be less than 1 hour, about 1 hour, about 1-2 hours, about 2-3 hours, about 3-4 hours, about 6 hours, about 12 hours, about 24 hours, about 48 hours, about 2-4 days, about 4-6 days, about 1 week, about 2 weeks, or more than 2 weeks.

[0153] In other embodiments, the CTLA4-Ig immunoadhesins disclosed herein are administered in a metronomic dosing regimen, or by continuous infusion or frequent administration without an extended rest period. Such metronomic administration may include administration at constant intervals without a rest period. Typically, such regimens encompass long-term low doses or continuous infusions for a longer period of time, such as 1-2 days, 1-2 weeks, 1-2 months, or up to 6 months or longer. Use of lower doses can minimize side effects and the need for rest periods.

[0154] In some embodiments, the CTLA4-Ig immunoadhesin disclosed herein and one or more other preventive or therapeutic agents are administered to a patient in cycles. Cycling therapy includes administering a first agent at one time, administering a second agent at a second time, optionally administering an additional agent at another time, optionally with a rest period, and then repeating the sequence of administration one or more times. The number of cycles is generally 2-10 times. Cycling therapy can reduce the development of resistance to one or more agents, can minimize side effects, or can improve efficacy.

[0155] Combination therapy

[0156] The CTLA4-Ig immunoadhesins disclosed herein can be co-administered with one or more other treatment regimens or therapeutic agents. Additional treatment regimens or therapeutic agents can be used to improve the efficacy or safety of the CTLA4-Ig immunoadhesins. Moreover, additional treatment regimens or therapeutic agents can be used to treat the same disease or comorbidity without changing the effect of the CTLA4-Ig immunoadhesin. For example, the CTLA4-Ig immunoadhesins disclosed herein can be administered to a patient together with chemotherapy, radiotherapy, or both.

[0157] The terms "in combination" and "co-administration" are not limited to the administration of the prophylactic or therapeutic agents at exactly the same time. Rather, it refers to the administration of the CTLA4-Ig immunoadhesin disclosed herein and other one or more agents in a certain order and within a certain time interval so that they can work together to provide an increased benefit over the CTLA4-Ig immunoadhesin or other one or more agents disclosed herein alone. In some embodiments, the CTLA4-Ig immunoadhesin disclosed herein and other one or more agents act additively and sometimes synergistically. Such molecules are suitable for being present in combination in an amount effective for the intended purpose. Skilled medical personnel can determine the appropriate dosage of each therapeutic agent and the appropriate administration schedule and method based on experience or taking into account the pharmacokinetics and mode of action of the agent.

[0158] The CTLA4-Ig immunoadhesins disclosed herein can be administered in combination with one or more other preventive or therapeutic agents, including but not limited to cytotoxic agents, chemotherapeutic agents, antibiotics, antifungal agents, antiviral agents, cytokines, growth inhibitors, antihormonal agents, kinase inhibitors, anti-angiogenic agents, cardioprotective drugs, immunostimulants, immunosuppressants, agents that promote blood cell proliferation, angiogenesis inhibitors, protein tyrosine kinase (PTK) inhibitors, other antibodies, Fc fusions, or CTLA4-Ig immunoadhesins, or other therapeutic agents. The therapy of the present invention can be combined with other immunotherapies. The therapy of the present invention can be combined with antagonists of chemokines or cytokines, including but not limited to antibodies and Fc fusions.

[0159] The CTLA4-Ig immunoadhesins disclosed herein can be combined with other treatment regimens. For example, in one embodiment, a patient who will be treated with the CTLA4-Ig immunoadhesins disclosed herein may also receive radiotherapy. Radiotherapy can be administered according to regimens commonly used in the art and known to those skilled in the art. Such therapies include, but are not limited to, cesium, iridium, iodine, or cobalt irradiation. Radiotherapy can be whole body irradiation, or can be localized to specific parts or tissues of the body, such as the lungs, bladder, or prostate. Optionally, radiotherapy can be administered as a single dose or multiple consecutive doses. Skilled medical personnel can empirically determine the appropriate dose of radiotherapy useful herein. According to another embodiment of the present invention, cancer cells are treated ex vivo using the CTLA4-Ig immunoadhesins disclosed herein and one or more other anti-cancer therapies. It is envisioned that such ex vivo treatment may be useful in bone marrow transplantation and, in particular, in autologous bone marrow transplantation. For example, treating cells or tissues containing cancer cells with CTLA4-Ig immunoadhesins and one or more other anti-cancer therapies, such as those described above, can be used to deplete or substantially deplete cancer cells before transplantation in a recipient patient. It is of course contemplated that the CTLA4-Ig immunoadhesins disclosed herein may be employed in combination with other therapeutic techniques such as surgery.

[0160] Although specific embodiments of the present invention have been described above for purposes of illustration, those skilled in the art will appreciate that numerous changes in detail may be made without departing from the invention as described in the appended claims.All references cited herein are incorporated in their entirety. Example

[0161] The following examples are provided to illustrate the present invention. These examples are not intended to limit the present invention to any particular application or principle of operation.

[0162] Example 1. Engineered CTLA4-Ig variants with enhanced binding to B7-1 and B7-2

[0163] The amino acid sequence of full-length human CTLA4 is provided at Figure 1 The extracellular domain (ECD) responsible for interaction with B7-1 and B7-2 is also provided in Figure 1 .

[0164] Immunoadhesins (Fc fusions) of CTLA4 can be constructed by linking the ECD (or a variant of the ECD) to the Fc region of IgG. The Fc region of native human IgG (IgG1, IgG2, IgG3, and IgG4) is provided in Figure 2 Although provided in Figure 2The IgG1 Fc comprises a 356D / 358L haplotype, other haplotypes or allotypes (e.g., 356E / 358M) may be used. The Fc region herein is defined as position 230 to the C-terminus based on the EU numbering scheme. Abatacept is an immunoadhesin (in which CTLA4 is linked to a modified IgG1 comprising a P238S substitution) Figure 2 The CTLA4-Ig immunoadhesins of the present invention may include a serine or a proline at position 238 (i.e., the CTLA4-Ig immunoadhesin may include 238S or 238P). Other variant forms of the IgG Fc region are also provided in Figure 2 , including an IgG2 Fc region with four IgG1 modifications in the lower hinge region (referred to as Fc(IgG2-233E / 234L / 235L / 236G).

[0165] The CTLA4 ECD can be linked to the Fc region via a variety of linkers. The linkers used in this study included sequences from human IgG constant chains, including the C-terminus and upper hinge of the CH1 domain. Exemplary linker sequences based on native IgG isotypes are provided in Figure 3 Modified linkers can be used. Exemplary linkers used in this study are modified IgG linkers (e.g., IgG1- or IgG2-based linkers) in which cysteine ​​is replaced by serine. In addition to the insertion of an N-terminal glutamine, abatacept uses a modified IgG1 linker with a cysteine ​​to serine substitution. Examples of such linkers are also provided in Figure 3 .

[0166] Examples of exemplary combinations of linkers and Fc regions used in this study are provided in Figure 4 These include the Fc region of abatacept, referred to as Ig(ab), and two fusions based on the IgG2 Fc region, referred to as Ig(G2) and Ig(G2-ELLG), which contain four IgG1 modifications (233E / 234L / 235L / 236G) built into the IgG2 Fc region in the lower hinge. Exemplary CTLA4-Ig immunoadhesins are provided at Figure 5 These include abatacept, also known as CTLA4-Ig(ab), an IgG2 Fc-based form of abatacept called CTLA4-Ig(G2), and belatacept, a variant form of abatacept with two substitutions, A29Y and L104E, in the CTLA4 portion that enhance affinity for B7-1 and B7-2.

[0167] In order to enhance the affinity of human CTLA4 for human B7-1 (CD80) and B7-2 (CD86), a rational structure-based approach was used to design CTLA4 variants. A high-resolution structure of the complex between human CTLA4 and human B7-1 (Stamper et al., 2001, Nature 410: 608-611) and B7-2 (Schwartz et al., 2001, Nature 410: 604-608) is available. The designed variant libraries are provided as follows: A29K, A29N, A29E, A29W, A29F, A29Y, A29H, A29Q, A29R, T30D, T30V, T30A, T30N, T30E, T30H, T30R, E31I, E31M, E31T, E31V, E31D, R33F, R33T, R33M, R33W, R33I, R33Y, R33L, R33E, R33Q, T35E, T35V, T35M, T35D, T35F, T35Y, A49T, A49F, A49Y, A49W, A49D, A49E, T51V, T51L, T51N, T51H, T51Q, T51E, T51S, T 51R, T51D, M53E, M53Q, M53Y, M53W, M53F, M53H, T59V, T59L, T59N, T59Y, T59H, T59Q, T59I, L61D, L61E, L6 1I, L61A, L61F, L61G, L61H, L61K, L61M, L61N, L61P, L61Q, L61R, L61S, L61T, L61V, L61W, L61Y, D63E, S64 K, S64R, S64Y, K93D, K93E, K93F, K93H, K93Q, K93R, K93T, K93V, K93W, K93Y, K93N, K93S, E95D, E95Q, E95Y , E95H, E95L, M97F, M97D, M97N, M97I, M97V, Y98F, Y98W, Y102F, Y102W, Y103F, Y103W, Y103H, Y103D, Y103E, Y103N, Y103Q, L104D, L104E, L104V, L104M, L104Y, L104W, L104F, L104H, G105D, G105E, I106E, and I106Y.

[0168] The gene encoding the CTLA4 protein was commercially synthesized (Blue Heron Biotechnologies, Bothell, WA) and subcloned into the mammalian expression vector pTT5 containing the human IgG constant region (Durocher Y et al., 2002, Nucleic Acids Res 30[2]:E9). Site-directed mutagenesis method Amino acid modifications were constructed using site-directed mutagenesis (Stratagene, La Jolla CA). Belatacept CTLA4(A29Y / L104E)-Ig(ab) was also constructed as a control. All DNA sequences were sequenced to confirm sequence fidelity. Lipofectamine TM The plasmid containing the CTLA4-Ig gene was transfected into 293E cells (Durocher Y, et al., 2002, Nucleic Acids Res 30[2]:E9; Biotechnology Research Institute, National Research Council Canada) in a small scale (3 ml) in a 6-well plate format and expressed in FreeStyle TM 293 medium (Invitrogen, Carlsbad CA). After 5 days of growth, the supernatant was screened for variant proteins that were targeted. After 5 days of growth, the supernatant was screened for variant proteins that were targeted using MabSelect TM Proteins were purified from culture supernatants using ELISA resin (GE Healthcare).

[0169] Surface plasmon resonance was used to screen variant CTLA4-Ig Fc fusion proteins for binding to B7-1 and B7-2. TM Binding measurements were performed using a Biacore 3000 instrument (Biacore). The sensor chip was derivatized with anti-His-tag mAb, followed by capture of B7-1-Ig or B7-2-Ig (both from R&D Systems) at 100 nM and 200 nM for 1.5 min. Variant and control CTLA4-Ig proteins were injected into HBS-EP buffer (Biacore) for 1 min, followed by dissociation for 2 min. Data were processed by zeroing the time and response before injecting the receptor and by subtracting appropriate nonspecific signals (the response of the reference channel and the injection of the running buffer). Dissociation rate constants (dissociation rates or k) were obtained using BIAevaluation software to fit the dissociation sensorgram. d or k off). The results of three separate binding experiments are provided in Table 1, along with the fold improvement or reduction in the off-rate for binding to the two antigens.

[0170] Table 1. Dissociation rates (k) of CTLA4-Ig variants binding to B7-1 and B7-2 off )

[0171]

[0172]

[0173]

[0174] Dissociation rate (k off ) is displayed in scientific E notation, where E represents the power of 10; multiple B7-1 = k combined with B7-1 off (Abatacept) / k off (variant); multiple B7-2 = k for binding to B7-2 off (Abatacept) / k off (variants); NB = no binding observed.

[0175] Relative to abatacept multiples (k off ) is shown in the figure Figure 6 As can be seen from Table 1 and Figure 6 It was observed that various substitutions showed slower dissociation (higher binding) than the abatacept parent protein.

[0176] Variants with slower off-rates to B7-1 and / or B7-2 than abatacept were re-expressed at a larger scale and purified as described above. Protein concentration was determined by absorbance at 280 nm. TM Binding affinity to B7-1 and B7-2 was measured. All variant CTLA4-Ig proteins were standardized to 1 uM and quality controlled by protein A binding. Anti-His-chips were generated as above, and B7-1 and B7-2 were fixed at 50 nM for 1 min and 100 nM for 2 min, respectively. CTLA4-Ig protein was diluted 2-fold from 50 nM to 25, 12.5 and 6.25 nM, injected for 1 min, and then dissociated for 2 min. Kinetic data were fitted to a 1:1 binding model (Langmuir) using BIAevaluation software to provide the dissociation rate constant (k d or k off ), association rate constant (k a or k on ), and equilibrium dissociation constant (KD or K D ). The binding affinities are provided in Table 2 (B7-1) and Table 3 (B7-2).

[0177] Table 2. B7-1 binding affinities and kinetic constants of CTLA4-Ig variants

[0178] Variants <![CDATA[k on (1 / Ms)]]> <![CDATA[k off (1 / s)]]> <![CDATA[K D (M)]]> <![CDATA[Multiplier K p > Abatacept 2.38E+06 1.64E-03 6.91E-10 1.00 Belacept 2.16E+06 7.75E-04 3.59E-10 1.92 A29K 9.18E+05 1.39E-03 1.52E-09 0.45 A29W 1.97E+06 1.42E-03 7.22E-10 0.96 A29Y 3.07E+06 1.26E-03 4.09E-10 1.69 A29H 2.34E+06 1.08E-03 4.62E-10 1.50 T51N 1.95E+06 3.16E-03 1.62E-09 0.43 M53 2.64E+06 1.18E-03 4.45E-10 1.55 L61D 3.26E+06 2.04E-03 6.26E-10 1.10 L61E 2.63E+06 1.65E-03 6.25E-10 1.11 L61G 2.76E+06 1.52E-03 5.49E-10 1.26 L61K 2.24E+06 1.85E-03 8.27E-10 0.84 L61N 2.60E+06 2.03E-03 7.82E-10 0.88 Q93 2.57E+06 8.75E-04 3.40E-10 2.03 K93R 1.16E+06 1.47E-03 1.26E-09 0.55 K93V 1.15E+06 7.54E-04 6.55E-10 1.05 Y103D 2.01E+06 0.0105 5.24E-09 0.13 Y103E 2.45E+06 0.0143 5.85E-09 0.12 Y103N 2.14E+06 0.0188 8.77E-09 0.08 Y103Q 1.83E+06 8.17E-03 4.48E-09 0.15 L104D 5.57E+05 2.11E-03 3.79E-09 0.18 L104E 2.47E+08 8.90E-04 3.60E-10 1.92 L104V 2.54E+06 1.54E-03 6.05E-10 1.14

[0179] k on = binding rate; k off = dissociation rate; K D = equilibrium dissociation constant; multiple K D =K D (Abatacept) / K D (Variant)

[0180] Table 3. B7-2 binding affinities and kinetic constants of CTLA4-Ig variants

[0181] Variants <![CDATA[k on (1 / Ms)]]> <![CDATA[k off (1 / s)]]> <![CDATA[K D (M)]]> <![CDATA[Multiplier K p > Abatacept 3.64E+06 1.66E-02 4.55E-09 1.00 Belacept 3.35E+06 2.18E-03 6.52E-10 6.98 A29K 1.55E+06 3.96E-03 2.55E-09 1.78 A29W 3.28E+06 4.74E-03 1.44E-09 3.16 A29Y 4.45E+06 6.29E-03 1.41E-09 3.23 A29H 3.35E+06 3.42E-03 1.02E-09 4.46 T51N 2.86E+06 5.07E-03 1.77E-09 2.57 M53 3.90E+06 1.17E-02 3.01E-09 1.51 L61D 4.51E+06 1.55E-02 3.44E-09 1.32 L61E 4.18E+06 1.30E-02 3.11E-09 1.46 L61G 3.54E+06 2.05E-02 5.79E-09 0.79 L61K 2.63E+06 2.76E-02 1.05E-08 0.43 L61N 3.45E+06 2.01E-02 5.81E-09 0.78 Q93 3.80E+06 8.43E-03 2.22E-09 2.05 K93R 1.79E+06 1.71E-02 9.55E-09 0.48 K93V 1.68E+06 1.22E-02 7.30E-09 0.62 Y103D 1.11E+06 9.28E-03 8.38E-09 0.54 Y103E 1.26E+06 8.38E-03 6.64E-09 0.69 Y103N 1.54E+06 0.0143 9.27E-09 0.49 Y103Q 1.53E+06 7.46E-03 4.89E-09 0.93 L104D 8.37E+05 1.75E-02 2.09E-08 0.22 L104E 3.93E+06 6.25E-03 1.59E-09 2.88 L104V 3.47E+06 1.47E-02 4.22E-09 1.08

[0182] k on = binding rate; k off = dissociation rate; K D = equilibrium dissociation constant; multiple K D =K D (Abatacept) / K D (Variant)

[0183] Based on the results of the single substitution screening, libraries of combinatorial variants and additional single substitution variants were designed. The new variants are listed in Tables 4 and 5. The variants were constructed, expressed and purified as described above. The binding to the B7 target was measured as described above, and the fitted kinetic rate constants and affinities are provided in Tables 4 (B7-1) and 5 (B7-2).

[0184] Table 4. B7-1 binding affinities and kinetic constants of CTLA4-Ig variants

[0185]

[0186]

[0187] k on = binding rate; k off = dissociation rate; K D = equilibrium dissociation constant;

[0188] Multiple K D =K D (Abatacept) / K D (variants); NB = no binding detected.

[0189] Table 5. B7-2 binding affinities and kinetic constants of CTLA4-Ig variants

[0190]

[0191] k on = binding rate; k off = dissociation rate; K D = equilibrium dissociation constant;

[0192] Multiple K D =K D (Abatacept) / K D (variants); NB = no binding detected.

[0193] Plots of CD80 and CD86 KD for all variants compared with abatacept and belatacept are shown in Figure 7 . Relative to the abatacept parent CTLA4-Ig, multiple combinatorial variants bind more tightly to both B7-1 (CD80) and B7-2 (CD86), providing a 3.6-fold improvement in binding to B7-1 and a 19.2-fold improvement in binding to B7-2. The best triple-substituted variant for B7-2 binding was T51N / L61E / K93Q (referred to as NEQ), which improved B7-2 affinity from 437pM to 40pM, and improved B7-1 affinity from 59pM to 36pM. The best quadruple-substituted variant for B7-2 binding was A29H / T51N / L61E / K93Q (referred to as HNEQ), which improved B7-2 affinity from 437pM to 23pM, and improved B7-1 affinity from 59pM to 16pM. A graph comparing the sensorgrams of the highest CTLA4-Ig concentrations for the HNEQ variant with abatacept and belatacept is shown in Figure 8 The amino acid sequences of these CTLA4 variants and CTLA4-Ig variant proteins are provided in Fig. 9 .

[0194] Example 2. Engineered CTLA4-Ig variants with greater in vitro T cell inhibitory activity

[0195] The ability of the NEQ and HNEQ variant CTLA4-Ig proteins to inhibit T cell proliferation was tested in a cell-based assay. Abatacept, Belatacept, and an anti-RSV IgG1 antibody not specific for B7-1 or B7-2 (negative control) were run as controls. In this assay, anti-CD3 antibody OKT3 and recombinant B7-2 Fc fusion (R&D Systems) were used to stimulate T cell activation and proliferation. U-shaped tissue culture plates were coated overnight at 4°C with 2ug / ml CD86-Fc and 0.5ug / ml anti-OKT3 in PBS. The plates were washed three times with PBS. Human peripheral blood mononuclear cells (PBMCs) were cultured using Ficoll-Paque TMT cells were purified by leukapheresis from anonymous healthy volunteers (HemaCare, Van Nuys, CA) using ELISA Plus density gradient (Amersham Biosciences, Newark, NJ). Human T cell enrichment kit (StemCell Technologies) was used to isolate T cells from PBMC and label them with CSFE (10uM). CTLA4-Ig protein variants and controls were added at 8 concentrations diluted 4-fold, with the highest concentration being 50ug / ml. Samples were run in duplicate. ~500,000 T cells were added to the coated plates and cultured at 37°C for 4 days. Control conditions were performed with cells in CD86-Fc / OKT3 coated wells and cells only (no coating). After 4 days in culture, FACSCanto2 TM Samples were analyzed for FITC staining (CSFE). Fig.10 The data in show that the tested CTLA4-Ig variants T51N / L61E / K93Q and A29H / T51N / L61E / K93Q outperform the parent CTLA4-Ig abatacept, which is consistent with their improved B7-1 and B7-2 affinities. Moreover, both the T51N / L61E / K93Q and A29H / T51N / L61E / K93Q variants showed greater inhibitory activity relative to belatacept, which is consistent with their greater B7-2 affinity.

[0196] Example 3. CTLA4-Ig immunoadhesin with enhanced binding to FcRn for prolonged in vivo half-life

[0197] The Fc region of the CTLA4-Ig protein is engineered to enhance affinity for the neonatal Fc receptor FcRn with the goal of improving serum half-life in vivo. Fc variants that improve FcRn binding and potentially provide improved pharmacokinetic characteristics include, but are not limited to, substitutions at positions 259, 307, 308, 311, 378, 426, 428, 434, and 436, including, but not limited to, for example, 259I, 307Q, 308F, 311I, 311V, 378V, 378T, 426V, 428L, 434S, 434H, 434F, 434Y, 434M, 436I, and 436V (USSN 12 / 341,769 filed 12 / 22 / 2008, expressly incorporated herein by reference). Other variants that increase Fc binding to FcRn include, but are not limited to: 250E, 250Q, 428L, 428F, 250Q / 428L (Hinton et al., 2004, J. Biol. Chem. 279(8):6213-6216, Hinton et al. 2006 Journal of Immunology 176:346-356), 256A, 272A, 286A, 305A, 307A, 311A, 312A, 376A, 378Q, 380A, 382A, 434A (Shields et al., Journal of 434F, 434Y, 252Y / 254T / 256E, 433K / 434F / 436H and 308T / 309P / 311S (Dall'Acqua et al., Journal of Immunology, 2002, 169:5171-5180, Dall'Acqua et al., 2006, The Journal of Biological Chemistry, 169:5171-5180, Dall'Acqua et al., 2006, The Journal of Biological Chemistry, 169:5171-5180, Dall'Acqua et al., 2006, The Journal of Biological Chemistry, 169:5171-5180, Dall'Acqua et al., 2006, The Journal of Biological Chemistry, 169:5171-5180, 281:23514-23524, incorporated by reference in its entirety).

[0198] Substitutions M428L and N434S that provide enhanced FcRn affinity and extended half-life were engineered into the Fc region of abatacept CTLA4-Ig(ab), CTLA4-Ig(G2) belatacept, CTLA4(HNEQ), and CTLA4(NEQ) variant Ig(G2-ELLG) forms. The amino acid sequences of these CTLA4-Ig variant proteins are provided in Fig.11 .

[0199] CTLA4-Ig variant proteins were constructed, expressed and purified as described above. TM Using Biacore in an antigen-mediated immunoadhesin capture / human FcRn analyte format TM 3000 instrument (Biacore TM ) measure the affinity of these variants to FcRn at pH 6.0. Using standard amine coupling method, B7-1 and B7-2 are fixed to CM5 chip at a density of 6500 and 8400RU respectively. The ligands are diluted to 200nM in pH 4.0 acetate buffer respectively. The surface is activated for 4min with full strength 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC)+N-hydroxysulfosuccinimide (Sulfo-NHS), and then B7-1 or B7-2 Fc fusion ligand (R&D Systems) is injected at 2ul / min for 15min. Finally, the surface is closed with ethanolamine. The capture of CTLA4-Ig protein is carried out in pH 6.0 phosphate buffer with 20nM (WT IgG1 Fc) or 10nM (M428L / N434S variant Fc) for 2 minutes to achieve 1500 or 700 RU respectively. Human FcRn analyte solution was then injected at concentrations of 500, 250 and 125 nM at the indicated concentrations, followed by regeneration of the B7 surface with pH 4.0 acetate + 500 mM NaCl buffer before the next cycle. Due to the presence of Fc-fusions on B7, there was a high background of hFcRn directly bound to the surface, so a series of concentrations of hFcRn were injected into the unimmobilized (empty) surface to manually subtract this background during Biaevaluation analysis. After background / drift subtraction and axis zeroing, the BIAevaluation software (Biacore TM ) The sensorgrams were fully fitted to a 1:1 Langmuir binding model.

[0200] Representative sensorgrams of abatacept binding to CTLA4-Ig(ab) and Fc-engineered form of CTLA4-Ig(ab-LS) (LS=428L / 434S) are shown in Fig.12 The fitted affinities of abatacept CTLA4-Ig(ab) and CTLA4-Ig(G2) and Fc-engineered forms of CTLA4-Ig(ab-LS) and CTLA4-Ig(G2-LS) for FcRn binding are provided in Table 6 and plotted in Fig.13 The results demonstrate the enhanced affinity of the Fc-engineered form of the CTLA4-Ig protein for FcRn, thereby demonstrating the potential of the Fc variant form for a longer in vivo half-life.

[0201] Table 6. Binding affinity of CTLA4-Ig protein to human FcRn at pH 6.0

[0202]

[0203] Example 4. CTLA4-Ig immunoadhesion with enhanced T cell suppressive activity in mixed lymphocyte reactions white

[0204] CTLA4-Ig variants with enhanced binding to FcRn were selected to test their T cell inhibitory activity.CTLA4-Ig proteins were tested in the cell-based assay described above, in which T cell proliferation was stimulated using anti-CD3 antibodies and B7-2 Fc fusions. Fig.14 The data in show potent and superior inhibitory activity of B7 affinity-enhanced CTLA4 variants (T51N / L61E / K93Q and A29H / T51N / L61E / K93Q) together with an Fc variant with FcRn affinity-enhanced (M428L / N434S).

[0205] The T cell suppressive activity of CTLA4-Ig variants was further measured by testing them in mixed lymphocyte reactions (also called mixed leukocyte reactions or MLRs). MLR is an in vitro method for testing T helper (TH) cell proliferation and for generating cytotoxic T lymphocyte (CTL) populations. When allogeneic (different MHC unit type) lymphocytes are cultured together, the TH cell population expands and subsequently the CTL population expands. The MHC / TCR and B7 / CD28 costimulatory pathways are critical for allogeneic reactions. Interleukin-2 (IL-2) secretion was used to monitor T cell activation. In two independent experiments, Ficoll-Paque TM Two different sets of human PBMCs were purified by leukapheresis from two different anonymous healthy volunteers (HemaCare, VanNuys, CA) using a 10x Plus density gradient (Amersham Biosciences, Newark, NJ). PBMCs were mixed at ~1.2×10E6 per well in each well with 300ul RPMI 1640 / 10% FBS. In one of the two experiments, PBMCs from donors 2336 and 3070 were mixed, and in the other experiment, PBMCs from donors 3070 and 3995 were mixed. CTLA4-Ig protein and anti-RSV IgG1 negative controls were prepared in a 10-point 4× serial dilution and added to the mixed PBMCs at the indicated final concentrations. PBMCs alone (independently) were also run as controls. Plates were cultured for 6 days. Supernatants were collected and analyzed using the IL-2 ELISA LegendMax TM The concentration of IL-2 was measured using a kit (BioLegend). The test results are provided in Fig.15 .

[0206] Fig.15 The data in support of the potent inhibitory activity of CTLA4-Ig variants and their potential for (abatacept). Unexpectedly, the NEQ variant is superior to the HNEQ variant, despite the HNEQ variant having a greater affinity for both B7-1 and B7-2 (Tables 4 and 5). The HNEQ variant improved the affinity for B7-1 by 3.6-fold and for B7-2 by 19.2-fold relative to abatacept, while the NEQ variant improved the affinity for B7-1 by 1.6-fold and for B7-2 by 10.8-fold relative to abatacept. The greater T cell suppressive activity of the NEQ variant may reflect the different biological roles of B7-1 and B7-2 in the immune response. Recent studies have demonstrated that B7-2 is the primary ligand for CD28, while B7-1 is the primary ligand for CTLA4, and that B7-2 is unable to recruit CTLA-4 to the immune synapse (Collins et al., 2002, Immunity 17:201-210; Jansson et al., 2005, J Immunol 175:1575-1585). Due to the role of endogenous CTLA4 in downregulating T cells (Alegre et al., 2001, Nat Rev Immunol 1:220-8), as well as its role in regulatory T cell (Treg)-mediated suppression of immune responses (Sakaguchi et al., 2009, International Immunology 21

[10] :1105-1111), the increased affinity for B7-1, which preferentially engages endogenous CTLA4, can inhibit natural inhibitors, thereby promoting T cell activation. In view of this, for therapeutic purposes, B7-2 may be a more important ligand to be inhibited, and accordingly, the best variant for optimizing CTLA4 may be a selective enhancement of affinity for B7-2 relative to B7-1. Substitutions that selectively improve affinity for B7-2 relative to B7-1 include, for example, A29H, A29K, T51N, L61E, and Y103Q. Note that for experimental purposes, testing this selectivity hypothesis may benefit from variants that provide opposite selectivity, i.e., improving binding to B7-1 relative to B7-2, including, for example, K93V, L61Q, and L104H. Overall, the results indicate that the NEQ combination variant T51N / L61E / K93Q is the best variant in terms of selectivity, providing a 10.8-fold affinity enhancement for B7-2, but only a small amount (1.6-fold) greater binding to B7-1. This affinity and selectivity profile is superior to Belatacept, which improved affinity for B7-2 by only 6.5-7 fold and for B7-1 by only 2.3 fold (Table 2-5).

[0207] Example 5. In vivo activity of novel CTLA4-Ig immunoadhesins

[0208] In vivo experiments were performed in mice to test the activity of engineered CTLA4-Ig variants. The ability of CTLA4-Ig protein to inhibit human immune responses to tetanus was performed in severe combined immunodeficient (SCID) mice transplanted with human peripheral blood leukocytes (PBL). SCID mice were selected as the animal model for this study because these mice are immunocompromised and will receive transplants of human PBMCs. The CTLA4-Ig protein used for in vivo studies was expressed in CHO cells (Biotechnology Research Institute, National Research Council Canada) and purified as described above.

[0209] Human peripheral blood mononuclear cells (PBMCs) were obtained from leukopacks (Hemacare, Van Nuys, CA) collected from random donors. TM Plus, GE Healthcare) purified PBMCs, resuspended in RPMI 1640 (Mediatech) and cultured at 3 × 10 7 The day before the PBMC injection, mice were injected ip with 100 μl of anti-sialo-deficient GM (Wako, Richmond, VA) to deplete mouse NK cells. The next day, mice were injected ip with 3×10 cells in a volume of 0.5 ml. 7 PBMC. A total of approximately 70 mice were injected. The day of cell injection was defined as study day 0. All animals were injected with PBMC on the same day.

[0210] After PBMC injection, mice were randomly divided and weighed. On the 7th day after PBMC injection, blood was collected from all mice via retro-orbital sinus / choroid plexus (OSP) puncture to determine human IgG levels (hIgG ELISA, ZeptoMetrix, Buffalo, NY). On the same day (the 7th day) after blood collection, mice were injected with 1mg / kg test product or injected with PBS as a negative control. Mice continued to receive injections every 3 or 4 days throughout the study. The test product in mg / kg was injected using the most recent body weight measurement results. On the 9th day, mice were injected with 15 μg tetanus toxoid (List Biological Labs, Campbell, CA, catalog number 191B) or injected with PBS. On the 21st day (12 days after antigen inoculation), blood was collected from all mice to determine human IgG and anti-tetanus IgG.

[0211] Blood samples (25-50ul) were collected using retro-orbital sinus / choroid plexus (OSP) on days 7 and 21 after PBMC transplantation (using local proparacaine anesthetic and inhalant isoflurane). The blood samples were transferred to serum separation tubes, allowed to stand for 30min-1 hour to allow blood to coagulate, and then spun in a centrifuge (3500rpm for 30min). The resulting serum was transferred to a polypropylene tube labeled with the study number, date, and collection time point. The serum samples were stored at -20°C. The serum concentration of anti-tetanus antibodies (anti-TT IgG) was measured using a standard anti-tetanus ELISA kit (IBL-America).

[0212] Fig.16 The results in demonstrate the activity of the affinity-enhanced NEQ variant CTLA4-Ig immunoadhesin relative to PBS+tetanus alone. Moreover, the data show that the NEQ variant has more potent inhibitory activity than the parent CTLA4-Ig abatacept. These data support the use of the CTLA4-Ig variants described herein for the treatment of immune-related disorders.

[0213] All references cited herein are expressly incorporated in their entirety by reference.While specific embodiments of the present invention have been described above for purposes of illustration, those skilled in the art will appreciate that many changes may be made to the details without departing from the invention as described in the appended claims. <110> XENCOR <120> Novel CTLA4-IG immunoadhesin <130> 067461-5149-WO <140> PCT / US2011 / 025747 <141> 2011-02-22 <150> US 61 / 412,309 <151> 2010-11-10 <150> US 61 / 334,806 <151> 2010-05-14 <150> US 61 / 306,311 <151> 2010-02-19 <160> 41 <170> PatentIn Version 3.5 <210> 1 <211> 124 <212> PRT <213> Artificial sequence <220> <223> Variant human CTLA4 first domain <220> <221> misc_feature <222> (29)..(29) <223> Where Xaa is alanine or histidine <220> <221> misc_feature <222> (51)..(51) <223> Where Xaa is threonine or asparagine <220> <221> misc_feature <222> (53)..(53) <223> Where Xaa is methionine or tyrosine <220> <221> misc_feature <222> (61)..(61) <223> Where Xaa is leucine or glutamic acid <220> <221> misc_feature <222> (93)..(93) <223> Where Xaa is lysine or glutamine <400> 1 Met His Val Ala Gln Pro Ala Val Val Leu Ala Ser Ser Arg Gly Ile 1 5 10 15 Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly Lys Xaa Thr Glu Val 20 25 30 Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln Val Thr Glu Val Cys 35 40 45 Ala Ala Xaa Tyr Xaa Met Gly Asn Glu Leu Thr Phe Xaa Asp Asp Ser 50 55 60 Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val Asn Leu Thr Ile Gln 65 70 75 80 Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile Cys Xaa Val Glu Leu 85 90 95 Met Tyr Pro Pro Pro Tyr Tyr Leu Gly Ile Gly Asn Gly Thr Gln Ile 100 105 110 Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser Asp 115 120 <210> 2 <211> 124 <212> PRT <213> Artificial sequence <220> <223> Variant human CTLA4 first domain <220> <221> misc_feature <222> (51)..(51) <223> Where Xaa is threonine or asparagine <220> <221> misc_feature <222> (53)..(53) <223> Where Xaa is methionine or tyrosine <220> <221> misc_feature <222> (61)..(61) <223> Where Xaa is leucine or glutamic acid <220> <221> misc_feature <222> (93)..(93) <223> Where Xaa is lysine or glutamine <400> 2 Met His Val Ala Gln Pro Ala Val Val Leu Ala Ser Ser Arg Gly Ile 1 5 10 15 Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly Lys His Thr Glu Val 20 25 30 Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln Val Thr Glu Val Cys 35 40 45 Ala Ala Xaa Tyr Xaa Met Gly Asn Glu Leu Thr Phe Xaa Asp Asp Ser 50 55 60 Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val Asn Leu Thr Ile Gln 65 70 75 80 Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile Cys Xaa Val Glu Leu 85 90 95 Met Tyr Pro Pro Pro Tyr Tyr Leu Gly Ile Gly Asn Gly Thr Gln Ile 100 105 110 Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser Asp 115 120 <210> 3 <211> 124 <212> PRT <213> Artificial sequence <220> <223> Variant human CTLA4 first domain <220> <221> misc_feature <222> (29)..(29) <223> Where Xaa is alanine or histidine <220> <221> misc_feature <222> (53)..(53) <223> Where Xaa is methionine or tyrosine <220> <221> misc_feature <222> (61)..(61) <223> Where Xaa is leucine or glutamic acid <220> <221> misc_feature <222> (93)..(93) <223> Where Xaa is lysine or glutamine <400> 3 Met His Val Ala Gln Pro Ala Val Val Leu Ala Ser Ser Arg Gly Ile 1 5 10 15 Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly Lys Xaa Thr Glu Val 20 25 30 Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln Val Thr Glu Val Cys 35 40 45 Ala Ala Asn Tyr Xaa Met Gly Asn Glu Leu Thr Phe Xaa Asp Asp Ser 50 55 60 Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val Asn Leu Thr Ile Gln 65 70 75 80 Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile Cys Xaa Val Glu Leu 85 90 95 Met Tyr Pro Pro Pro Tyr Tyr Leu Gly Ile Gly Asn Gly Thr Gln Ile 100 105 110 Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser Asp 115 120 <210> 4 <211> 124 <212> PRT <213> Artificial sequence <220> <223> Variant human CTLA4 first domain <220> <221> misc_feature <222> (29)..(29) <223> Where Xaa is alanine, glutamic acid, phenylalanine, histidine, Lysine, asparagine, glutamine, or arginine <220> <221> misc_feature <222> (30)..(30) <223> Where Xaa is threonine, histidine or valine <220> <221> misc_feature <222> (31)..(31) <223> Where Xaa is glutamic acid, aspartic acid, isoleucine, Methionine, threonine, or valine <220> <221> misc_feature <222> (33)..(33) <223> Where Xaa is arginine, glutamic acid, phenylalanine, isoleucine, Leucine, methionine, glutamine, threonine, tryptophan or Tyrosine <220> <221> misc_feature <222> (35)..(35) <223> Where Xaa is threonine, aspartic acid, glutamic acid, Phenylalanine, methionine, valine, or tyrosine <220> <221> misc_feature <222> (49)..(49) <223> Where Xaa is alanine, aspartic acid, glutamic acid, Phenylalanine, threonine, tryptophan, or tyrosine <220> <221> misc_feature <222> (51)..(51) <223> Where Xaa is threonine, aspartic acid, glutamic acid, histidine, Leucine, asparagine, glutamine, arginine, serine, or valine <220> <221> misc_feature <222> (53)..(53) <223> Where Xaa is methionine, glutamic acid, phenylalanine, histidine, Glutamine, tryptophan, or tyrosine <220> <221> misc_feature <222> (59)..(59) <223> Where Xaa is threonine, histidine, isoleucine, leucine, Asparagine, glutamine, valine or tyrosine <220> <221> misc_feature <222> (61)..(61) <223> Where Xaa is leucine, alanine, glutamic acid, phenylalanine, Glycine, histidine, isoleucine, lysine, methionine, asparagine, Proline, glutamine, arginine, serine, threonine, valine, Tryptophan or tyrosine <220> <221> misc_feature <222> (63)..(63) <223> Where Xaa is aspartic acid or glutamic acid <220> <221> misc_feature <222> (64)..(64) <223> Where Xaa is serine, lysine, arginine or tyrosine <220> <221> misc_feature <222> (93)..(93) <223> Where Xaa is lysine, aspartic acid, glutamic acid, phenylalanine, Histidine, asparagine, glutamine, arginine, serine, threonine, Valine, tryptophan, or tyrosine <220> <221> misc_feature <222> (95)..(95) <223> Where Xaa is glutamic acid, aspartic acid, histidine, leucine, Glutamine or tyrosine <220> <221> misc_feature <222> (97)..(97) <223> Where Xaa is methionine, aspartic acid, phenylalanine, Isoleucine, asparagine, or valine <220> <221> misc_feature <222> (98)..(98) <223> Where Xaa is tyrosine, phenylalanine or tryptophan <220> <221> misc_feature <222> (102)..(102) <223> Where Xaa is tyrosine, phenylalanine or tryptophan <220> <221> misc_feature <222> (103)..(103) <223> Where Xaa is tyrosine, aspartic acid, glutamic acid, Phenylalanine, histidine, asparagine, glutamine, or tryptophan <220> <221> misc_feature <222> (104)..(104) <223> Where Xaa is leucine, phenylalanine, histidine, methionine, Valine or Tyrosine <220> <221> misc_feature <222> (105)..(105) <223> Where Xaa is glycine, aspartic acid or glutamic acid <220> <221> misc_feature <222> (106)..(106) <223> Where Xaa is isoleucine, glutamic acid or tyrosine <400> 4 Met His Val Ala Gln Pro Ala Val Val Leu Ala Ser Ser Arg Gly Ile 1 5 10 15 Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly Lys Xaa Xaa Xaa Val 20 25 30 Xaa Val Xaa Val Leu Arg Gln Ala Asp Ser Gln Val Thr Glu Val Cys 35 40 45 Xaa Ala Xaa Tyr Xaa Met Gly Asn Glu Leu Xaa Phe Xaa Asp Xaa Xaa 50 55 60 Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val Asn Leu Thr Ile Gln 65 70 75 80 Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile Cys Xaa Val Xaa Leu 85 90 95 Xaa Xaa Pro Pro Pro Xaa Xaa Xaa Xaa Xaa Gly Asn Gly Thr Gln Ile 100 105 110 Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser Asp 115 120 <210> 5 <211> 223 <212> PRT <213> Homo sapiens <400> 5 Met Ala Cys Leu Gly Phe Gln Arg His Lys Ala Gln Leu Asn Leu Ala 1 5 10 15 Thr Arg Thr Trp Pro Cys Thr Leu Leu Phe Phe Leu Leu Phe Ile Pro 20 25 30 Val Phe Cys Lys Ala Met His Val Ala Gln Pro Ala Val Val Leu Ala 35 40 45 Ser Ser Arg Gly Ile Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly 50 55 60 Lys Ala Thr Glu Val Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln 65 70 75 80 Val Thr Glu Val Cys Ala Ala Thr Tyr Met Met Gly Asn Glu Leu Thr 85 90 95 Phe Leu Asp Asp Ser Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val 100 105 110 Asn Leu Thr Ile Gln Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile 115 120 125 Cys Lys Val Glu Leu Met Tyr Pro Pro Pro Tyr Tyr Leu Gly Ile Gly 130 135 140 Asn Gly Thr Gln Ile Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser 145 150 155 160 Asp Phe Leu Leu Trp Ile Leu Ala Ala Val Ser Ser Gly Leu Phe Phe 165 170 175 Tyr Ser Phe Leu Leu Thr Ala Val Ser Leu Ser Lys Met Leu Lys Lys 180 185 190 Arg Ser Pro Leu Thr Thr Gly Val Tyr Val Lys Met Pro Pro Thr Glu 195 200 205 Pro Glu Cys Glu Lys Gln Phe Gln Pro Tyr Phe Ile Pro Ile Asn 210 215 220 <210> 6 <211> 124 <212> PRT <213> Homo sapiens <400> 6 Met His Val Ala Gln Pro Ala Val Val Leu Ala Ser Ser Arg Gly Ile 1 5 10 15 Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly Lys Ala Thr Glu Val 20 25 30 Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln Val Thr Glu Val Cys 35 40 45 Ala Ala Thr Tyr Met Met Gly Asn Glu Leu Thr Phe Leu Asp Asp Ser 50 55 60 Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val Asn Leu Thr Ile Gln 65 70 75 80 Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile Cys Lys Val Glu Leu 85 90 95 Met Tyr Pro Pro Pro Tyr Tyr Leu Gly Ile Gly Asn Gly Thr Gln Ile 100 105 110 Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser Asp 115 120 <210> 7 <211> 124 <212> PRT <213> Homo sapiens <400> 7 Met His Val Ala Gln Pro Ala Val Val Leu Ala Ser Ser Arg Gly Ile 1 5 10 15 Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly Lys Tyr Thr Glu Val 20 25 30 Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln Val Thr Glu Val Cys 35 40 45 Ala Ala Thr Tyr Met Met Gly Asn Glu Leu Thr Phe Leu Asp Asp Ser 50 55 60 Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val Asn Leu Thr Ile Gln 65 70 75 80 Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile Cys Lys Val Glu Leu 85 90 95 Met Tyr Pro Pro Pro Tyr Tyr Glu Gly Ile Gly Asn Gly Thr Gln Ile 100 105 110 Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser Asp 115 120 <210> 8 <211> 124 <212> PRT <213> Artificial sequence <220> <223> consensus sequence <220> <221> misc_feature <222> (29)..(29) <223> Where Xaa is alanine or histidine <220> <221> misc_feature <222> (51)..(51) <223> Where Xaa is threonine or asparagine <220> <221> misc_feature <222> (53)..(53) <223> Where Xaa is methionine or tyrosine <220> <221> misc_feature <222> (61)..(61) <223> Where Xaa is leucine or glutamic acid <220> <221> misc_feature <222> (93)..(93) <223> Where Xaa is lysine or glutamine <400> 8 Met His Val Ala Gln Pro Ala Val Val Leu Ala Ser Ser Arg Gly Ile 1 5 10 15 Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly Lys Xaa Thr Glu Val 20 25 30 Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln Val Thr Glu Val Cys 35 40 45 Ala Ala Xaa Tyr Xaa Met Gly Asn Glu Leu Thr Phe Xaa Asp Asp Ser 50 55 60 Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val Asn Leu Thr Ile Gln 65 70 75 80 Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile Cys Xaa Val Glu Leu 85 90 95 Met Tyr Pro Pro Pro Tyr Tyr Leu Gly Ile Gly Asn Gly Thr Gln Ile 100 105 110 Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser Asp 115 120 <210> 9 <211> 218 <212> PRT <213> Homo sapiens <400> 9 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 1 5 10 15 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 20 25 30 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 35 40 45 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 50 55 60 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 65 70 75 80 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 85 90 95 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 100 105 110 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu 115 120 125 Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 130 135 140 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 145 150 155 160 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 165 170 175 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 180 185 190 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 195 200 205 Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 210 215 <210> 10 <211> 217 <212> PRT <213> Homo sapiens <400> 10 Pro Ala Pro Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 1 5 10 15 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 20 25 30 Val Val Asp Val Ser His Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr 35 40 45 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 50 55 60 Gln Phe Asn Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Val His 65 70 75 80 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 85 90 95 Gly Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Gln 100 105 110 Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met 115 120 125 Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 130 135 140 Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn 145 150 155 160 Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu 165 170 175 Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val 180 185 190 Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln 195 200 205 Lys Ser Leu Ser Leu Ser Pro Gly Lys 210 215 <210> 11 <211> 218 <212> PRT <213> Homo sapiens <400> 11 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 1 5 10 15 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 20 25 30 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Gln Phe Lys Trp 35 40 45 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 50 55 60 Glu Gln Tyr Asn Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Leu 65 70 75 80 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 85 90 95 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly 100 105 110 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu 115 120 125 Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 130 135 140 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Ser Gly Gln Pro Glu Asn 145 150 155 160 Asn Tyr Asn Thr Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe 165 170 175 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 180 185 190 Ile Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn Arg Phe Thr 195 200 205 Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 210 215 <210> 12 <211> 218 <212> PRT <213> Homo sapiens <400> 12 Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 1 5 10 15 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 20 25 30 Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp 35 40 45 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 50 55 60 Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 65 70 75 80 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 85 90 95 Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 100 105 110 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu 115 120 125 Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 130 135 140 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 145 150 155 160 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 165 170 175 Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn 180 185 190 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 195 200 205 Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys 210 215 <210> 13 <211> 218 <212> PRT <213> Homo sapiens <400> 13 Pro Ala Pro Glu Leu Leu Gly Gly Ser Ser Val Phe Leu Phe Pro Pro 1 5 10 15 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 20 25 30 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 35 40 45 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 50 55 60 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 65 70 75 80 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 85 90 95 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 100 105 110 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu 115 120 125 Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 130 135 140 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 145 150 155 160 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 165 170 175 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 180 185 190 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 195 200 205 Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 210 215 <210> 14 <211> 218 <212> PRT <213> Homo sapiens <400> 14 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 1 5 10 15 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 20 25 30 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Gln Phe Asn Trp 35 40 45 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 50 55 60 Glu Gln Phe Asn Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Val 65 70 75 80 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 85 90 95 Lys Gly Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly 100 105 110 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu 115 120 125 Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 130 135 140 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 145 150 155 160 Asn Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe 165 170 175 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 180 185 190 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 195 200 205 Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 210 215 <210> 15 <211> 218 <212> PRT <213> Homo sapiens <400> 15 Pro Ala Pro Glu Leu Leu Gly Gly Ser Ser Val Phe Leu Phe Pro Pro 1 5 10 15 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 20 25 30 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Gln Phe Asn Trp 35 40 45 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 50 55 60 Glu Gln Phe Asn Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Val 65 70 75 80 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 85 90 95 Lys Gly Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly 100 105 110 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu 115 120 125 Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 130 135 140 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 145 150 155 160 Asn Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe 165 170 175 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 180 185 190 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 195 200 205 Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 210 215 <210> 16 <211> 14 <212> PRT <213> Artificial sequence <220> <223> Linker (IgG1) (EU No. 216-229) <400> 16 Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 1 5 10 <210> 17 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Linker (IgG2) (EU No. 216-229) <400> 17 Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys 1 5 10 <210> 18 <211> 61 <212> PRT <213> Artificial sequence <220> <223> Linker (IgG3) (EU No. 216-229) <400> 18 Glu Leu Lys Thr Pro Leu Gly Asp Thr Thr His Thr Cys Pro Arg Cys 1 5 10 15 Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys Pro 20 25 30 Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys Pro Glu 35 40 45 Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys 50 55 60 <210> 19 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Linker (IgG4) (EU No. 216-229) <400> 19 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Ser Cys 1 5 10 <210> 20 <211> 14 <212> PRT <213> Artificial sequence <220> <223> Linker (IgG1-220S / 226S / 229S) (EU No. 216-229) <400> 20 Glu Pro Lys Ser Ser Asp Lys Thr His Thr Ser Pro Pro Ser 1 5 10 <210> twenty one <211> 11 <212> PRT <213> Artificial sequence <220> <223> Connector (IGG2-219S / 220S / 226S / 229S) <400> twenty one Glu Arg Lys Ser Ser Val Glu Ser Pro Pro Ser 1 5 10 <210> twenty two <211> 15 <212> PRT <213> Artificial sequence <220> <223> Adapter (Q-IgG1-220S / 226S / 229S) (aka Abatacept adapter) <400> twenty two Gln Glu Pro Lys Ser Ser Asp Lys Thr His Thr Ser Pro Pro Ser 1 5 10 15 <210> twenty three <211> 12 <212> PRT <213> Artificial sequence <220> <223> Linker (Q-IgG2-219S / 220S / 226S / 229S) <400> twenty three Gln Glu Arg Lys Ser Ser Val Glu Ser Pro Pro Ser 1 5 10 <210> twenty four <211> 233 <212> PRT <213> Artificial sequence <220> <223> Ig(ab) [Linker (Q-IgG1-220S / 226S / 229S) + Fc (IgG1-238S) <400> twenty four Gln Glu Pro Lys Ser Ser Asp Lys Thr His Thr Ser Pro Pro Ser Pro 1 5 10 15 Ala Pro Glu Leu Leu Gly Gly Ser Ser Val Phe Leu Phe Pro Pro Lys 20 25 30 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 35 40 45 Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 50 55 60 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 65 70 75 80 Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 85 90 95 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 100 105 110 Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln 115 120 125 Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu 130 135 140 Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 145 150 155 160 Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn 165 170 175 Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 180 185 190 Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val 195 200 205 Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln 210 215 220 Lys Ser Leu Ser Leu Ser Pro Gly Lys 225 230 <210> 25 <211> 233 <212> PRT <213> Artificial Sequence <220> <223> Ig(ab-238P) [Linker(Q-IgG1-220S / 226S / 229S)+Fc(IgG1)] <400> 25 Gln Glu Pro Lys Ser Ser Asp Lys Thr His Thr Ser Pro Pro Ser Pro 1 5 10 15 Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 20 25 30 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 35 40 45 Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 50 55 60 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 65 70 75 80 Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 85 90 95 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 100 105 110 Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln 115 120 125 Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu 130 135 140 Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 145 150 155 160 Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn 165 170 175 Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 180 185 190 Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val 195 200 205 Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln 210 215 220 Lys Ser Leu Ser Leu Ser Pro Gly Lys 225 230 <210> 26 <211> 229 <212> PRT <213> Artificial Sequence <220> <223> Ig(G2) [Linker(Q-IgG2-219S / 220S / 226S / 229S)+Fc(IgG2)] <400> 26 Gln Glu Arg Lys Ser Ser Val Glu Ser Pro Pro Ser Pro Ala Pro Pro 1 5 10 15 Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45 Ser His Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 50 55 60 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser 65 70 75 80 Thr Phe Arg Val Val Ser Val Leu Thr Val Val His Gln Asp Trp Leu 85 90 95 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ala 100 105 110 Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Gln Pro Arg Glu Pro 115 120 125 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 130 135 140 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 160 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 165 170 175 Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 180 185 190 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 195 200 205 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 210 215 220 Leu Ser Pro Gly Lys 225 <210> 27 <211> 233 <212> PRT <213> Artificial Sequence <220> <223> Ig(G2-ELLG) [Linker (Q-IgG1-220S / 226S / 229S) + Fc (IgG2-233E / 234L / 235L / 236G)] <400> 27 Gln Glu Pro Lys Ser Ser Asp Lys Thr His Thr Ser Pro Pro Ser Pro 1 5 10 15 Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 20 25 30 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 35 40 45 Val Val Asp Val Ser His Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr 50 55 60 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 65 70 75 80 Gln Phe Asn Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Val His 85 90 95 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 100 105 110 Gly Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Gln 115 120 125 Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met 130 135 140 Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 145 150 155 160 Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn 165 170 175 Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu 180 185 190 Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val 195 200 205 Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln 210 215 220 Lys Ser Leu Ser Leu Ser Pro Gly Lys 225 230 <210> 28 <211> 357 <212> PRT <213> Artificial Sequence <220> <223> Abatacept CTLA4-Ig(ab) (XENP8420) <400> 28 Met His Val Ala Gln Pro Ala Val Val Leu Ala Ser Ser Arg Gly Ile 1 5 10 15 Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly Lys Ala Thr Glu Val 20 25 30 Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln Val Thr Glu Val Cys 35 40 45 Ala Ala Thr Tyr Met Met Gly Asn Glu Leu Thr Phe Leu Asp Asp Ser 50 55 60 Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val Asn Leu Thr Ile Gln 65 70 75 80 Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile Cys Lys Val Glu Leu 85 90 95 Met Tyr Pro Pro Pro Tyr Tyr Leu Gly Ile Gly Asn Gly Thr Gln Ile 100 105 110 Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser Asp Gln Glu Pro Lys 115 120 125 Ser Ser Asp Lys Thr His Thr Ser Pro Pro Ser Pro Ala Pro Glu Leu 130 135 140 Leu Gly Gly Ser Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 145 150 155 160 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 165 170 175 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 180 185 190 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 195 200 205 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 210 215 220 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 225 230 235 240 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 245 250 255 Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln 260 265 270 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 275 280 285 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 290 295 300 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 305 310 315 320 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 325 330 335 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 340 345 350 Leu Ser Pro Gly Lys 355 <210> 29 <211> 353 <212> PRT <213> Artificial Sequence <220> <223> CTLA4-Ig(G2) (XENP8445) <400> 29 Met His Val Ala Gln Pro Ala Val Val Leu Ala Ser Ser Arg Gly Ile 1 5 10 15 Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly Lys Ala Thr Glu Val 20 25 30 Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln Val Thr Glu Val Cys 35 40 45 Ala Ala Thr Tyr Met Met Gly Asn Glu Leu Thr Phe Leu Asp Asp Ser 50 55 60 Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val Asn Leu Thr Ile Gln 65 70 75 80 Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile Cys Lys Val Glu Leu 85 90 95 Met Tyr Pro Pro Pro Tyr Tyr Leu Gly Ile Gly Asn Gly Thr Gln Ile 100 105 110 Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser Asp Gln Glu Arg Lys 115 120 125 Ser Ser Val Glu Ser Pro Pro Ser Pro Ala Pro Pro Val Ala Gly Pro 130 135 140 Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 145 150 155 160 Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 165 170 175 Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 180 185 190 Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Val 195 200 205 Val Ser Val Leu Thr Val Val His Gln Asp Trp Leu Asn Gly Lys Glu 210 215 220 Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ala Pro Ile Glu Lys 225 230 235 240 Thr Ile Ser Lys Thr Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 245 250 255 Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr 260 265 270 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 275 280 285 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Met Leu 290 295 300 Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 305 310 315 320 Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu 325 330 335 Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 340 345 350 Lys <210> 30 <211> 357 <212> PRT <213> Artificial Sequence <220> <223> Belatacept CTLA4(29Y / 104E)-Ig(ab) (XENP8448) <400> 30 Met His Val Ala Gln Pro Ala Val Val Leu Ala Ser Ser Arg Gly Ile 1 5 10 15 Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly Lys Tyr Thr Glu Val 20 25 30 Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln Val Thr Glu Val Cys 35 40 45 Ala Ala Thr Tyr Met Met Gly Asn Glu Leu Thr Phe Leu Asp Asp Ser 50 55 60 Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val Asn Leu Thr Ile Gln 65 70 75 80 Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile Cys Lys Val Glu Leu 85 90 95 Met Tyr Pro Pro Pro Tyr Tyr Glu Gly Ile Gly Asn Gly Thr Gln Ile 100 105 110 Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser Asp Gln Glu Pro Lys 115 120 125 Ser Ser Asp Lys Thr His Thr Ser Pro Pro Ser Pro Ala Pro Glu Leu 130 135 140 Leu Gly Gly Ser Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 145 150 155 160 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 165 170 175 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 180 185 190 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 195 200 205 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 210 215 220 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 225 230 235 240 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 245 250 255 Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln 260 265 270 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 275 280 285 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 290 295 300 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 305 310 315 320 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 325 330 335 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 340 345 350 Leu Ser Pro Gly Lys 355 <210> 31 <211> 124 <212> PRT <213> Artificial Sequence <220> <223> CTLA4(HNEQ) (29H / 51N / 61E / 93Q) (H1.135) <400> 31 Met His Val Ala Gln Pro Ala Val Val Leu Ala Ser Ser Arg Gly Ile 1 5 10 15 Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly Lys His Thr Glu Val 20 25 30 Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln Val Thr Glu Val Cys 35 40 45 Ala Ala Asn Tyr Met Met Gly Asn Glu Leu Thr Phe Glu Asp Asp Ser 50 55 60 Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val Asn Leu Thr Ile Gln 65 70 75 80 Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile Cys Gln Val Glu Leu 85 90 95 Met Tyr Pro Pro Pro Tyr Tyr Leu Gly Ile Gly Asn Gly Thr Gln Ile 100 105 110 Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser Asp 115 120 <210> 32 <211> 124 <212> PRT <213> Artificial Sequence <220> <223> CTLA4(NEQ) (51N / 61E / 93Q) (H1.144) <400> 32 Met His Val Ala Gln Pro Ala Val Val Leu Ala Ser Ser Arg Gly Ile 1 5 10 15 Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly Lys Ala Thr Glu Val 20 25 30 Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln Val Thr Glu Val Cys 35 40 45 Ala Ala Asn Tyr Met Met Gly Asn Glu Leu Thr Phe Glu Asp Asp Ser 50 55 60 Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val Asn Leu Thr Ile Gln 65 70 75 80 Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile Cys Gln Val Glu Leu 85 90 95 Met Tyr Pro Pro Pro Tyr Tyr Leu Gly Ile Gly Asn Gly Thr Gln Ile 100 105 110 Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser Asp 115 120 <210> 33 <211> 357 <212> PRT <213> Artificial Sequence <220> <223> CTLA4(HNEQ)-Ig(ab) (XENP9360) <400> 33 Met His Val Ala Gln Pro Ala Val Val Leu Ala Ser Ser Arg Gly Ile 1 5 10 15 Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly Lys His Thr Glu Val 20 25 30 Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln Val Thr Glu Val Cys 35 40 45 Ala Ala Asn Tyr Met Met Gly Asn Glu Leu Thr Phe Glu Asp Asp Ser 50 55 60 Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val Asn Leu Thr Ile Gln 65 70 75 80 Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile Cys Gln Val Glu Leu 85 90 95 Met Tyr Pro Pro Pro Tyr Tyr Leu Gly Ile Gly Asn Gly Thr Gln Ile 100 105 110 Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser Asp Gln Glu Pro Lys 115 120 125 Ser Ser Asp Lys Thr His Thr Ser Pro Pro Ser Pro Ala Pro Glu Leu 130 135 140 Leu Gly Gly Ser Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 145 150 155 160 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 165 170 175 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 180 185 190 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 195 200 205 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 210 215 220 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 225 230 235 240 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 245 250 255 Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln 260 265 270 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 275 280 285 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 290 295 300 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 305 310 315 320 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 325 330 335 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 340 345 350 Leu Ser Pro Gly Lys 355 <210> 34 <211> 357 <212> PRT <213> Artificial Sequence <220> <223> CTLA4(NEQ)-Ig(ab) (XENP9369) <400> 34 Met His Val Ala Gln Pro Ala Val Val Leu Ala Ser Ser Arg Gly Ile 1 5 10 15 Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly Lys Ala Thr Glu Val 20 25 30 Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln Val Thr Glu Val Cys 35 40 45 Ala Ala Asn Tyr Met Met Gly Asn Glu Leu Thr Phe Glu Asp Asp Ser 50 55 60 Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val Asn Leu Thr Ile Gln 65 70 75 80 Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile Cys Gln Val Glu Leu 85 90 95 Met Tyr Pro Pro Pro Tyr Tyr Leu Gly Ile Gly Asn Gly Thr Gln Ile 100 105 110 Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser Asp Gln Glu Pro Lys 115 120 125 Ser Ser Asp Lys Thr His Thr Ser Pro Pro Ser Pro Ala Pro Glu Leu 130 135 140 Leu Gly Gly Ser Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 145 150 155 160 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 165 170 175 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 180 185 190 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 195 200 205 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 210 215 220 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 225 230 235 240 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 245 250 255 Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln 260 265 270 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 275 280 285 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 290 295 300 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 305 310 315 320 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 325 330 335 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 340 345 350 Leu Ser Pro Gly Lys 355 <210> 35 <211> 357 <212> PRT <213> Artificial Sequence <220> <223> Abatacept CTLA4-Ig (ab-428L / 434S) (XENP8441) <400> 35 Met His Val Ala Gln Pro Ala Val Val Leu Ala Ser Ser Arg Gly Ile 1 5 10 15 Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly Lys Ala Thr Glu Val 20 25 30 Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln Val Thr Glu Val Cys 35 40 45 Ala Ala Thr Tyr Met Met Gly Asn Glu Leu Thr Phe Leu Asp Asp Ser 50 55 60 Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val Asn Leu Thr Ile Gln 65 70 75 80 Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile Cys Lys Val Glu Leu 85 90 95 Met Tyr Pro Pro Pro Tyr Tyr Leu Gly Ile Gly Asn Gly Thr Gln Ile 100 105 110 Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser Asp Gln Glu Pro Lys 115 120 125 Ser Ser Asp Lys Thr His Thr Ser Pro Pro Ser Pro Ala Pro Glu Leu 130 135 140 Leu Gly Gly Ser Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 145 150 155 160 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 165 170 175 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 180 185 190 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 195 200 205 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 210 215 220 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 225 230 235 240 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 245 250 255 Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln 260 265 270 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 275 280 285 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 290 295 300 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 305 310 315 320 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 325 330 335 Val Leu His Glu Ala Leu His Ser His Tyr Thr Gln Lys Ser Leu Ser 340 345 350 Leu Ser Pro Gly Lys 355 <210> 36 <211> 353 <212> PRT <213> Artificial sequence <220> <223> CTLA4-Ig(G2-428L / 434S) (XENP8447) <400> 36 Met His Val Ala Gln Pro Ala Val Val Leu Ala Ser Ser Arg Gly Ile 1 5 10 15 Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly Lys Ala Thr Glu Val 20 25 30 Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln Val Thr Glu Val Cys 35 40 45 Ala Ala Thr Tyr Met Met Gly Asn Glu Leu Thr Phe Leu Asp Asp Ser 50 55 60 Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val Asn Leu Thr Ile Gln 65 70 75 80 Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile Cys Lys Val Glu Leu 85 90 95 Met Tyr Pro Pro Pro Tyr Tyr Leu Gly Ile Gly Asn Gly Thr Gln Ile 100 105 110 Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser Asp Gln Glu Arg Lys 115 120 125 Ser Ser Val Glu Ser Pro Pro Ser Pro Ala Pro Pro Val Ala Gly Pro 130 135 140 Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 145 150 155 160 Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 165 170 175 Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 180 185 190 Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Val 195 200 205 Val Ser Val Leu Thr Val Val His Gln Asp Trp Leu Asn Gly Lys Glu 210 215 220 Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ala Pro Ile Glu Lys 225 230 235 240 Thr Ile Ser Lys Thr Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 245 250 255 Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr 260 265 270 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 275 280 285 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Met Leu 290 295 300 Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 305 310 315 320 Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Leu His Glu 325 330 335 Ala Leu His Ser His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 340 345 350 Lys <210> 37 <211> 357 <212> PRT <213> Artificial sequence <220> <223> CTLA4(HNEQ)-Ig(G2-ELLG-428L / 434S) (XENP9523) <400> 37 Met His Val Ala Gln Pro Ala Val Val Leu Ala Ser Ser Arg Gly Ile 1 5 10 15 Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly Lys His Thr Glu Val 20 25 30 Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln Val Thr Glu Val Cys 35 40 45 Ala Ala Asn Tyr Met Met Gly Asn Glu Leu Thr Phe Glu Asp Asp Ser 50 55 60 Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val Asn Leu Thr Ile Gln 65 70 75 80 Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile Cys Gln Val Glu Leu 85 90 95 Met Tyr Pro Pro Pro Tyr Tyr Leu Gly Ile Gly Asn Gly Thr Gln Ile 100 105 110 Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser Asp Gln Glu Pro Lys 115 120 125 Ser Ser Asp Lys Thr His Thr Ser Pro Pro Ser Pro Ala Pro Glu Leu 130 135 140 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 145 150 155 160 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 165 170 175 Ser His Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 180 185 190 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser 195 200 205 Thr Phe Arg Val Val Ser Val Leu Thr Val Val His Gln Asp Trp Leu 210 215 220 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ala 225 230 235 240 Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Gln Pro Arg Glu Pro 245 250 255 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 260 265 270 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 275 280 285 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 290 295 300 Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 305 310 315 320 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 325 330 335 Val Leu His Glu Ala Leu His Ser His Tyr Thr Gln Lys Ser Leu Ser 340 345 350 Leu Ser Pro Gly Lys 355 <210> 38 <211> 357 <212> PRT <213> Artificial Sequence <220> <223> CTLA4(NEQ)-Ig(G2-ELLG-428L / 434S) (XENP9524) <400> 38 Met His Val Ala Gln Pro Ala Val Val Leu Ala Ser Ser Arg Gly Ile 1 5 10 15 Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly Lys Ala Thr Glu Val 20 25 30 Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln Val Thr Glu Val Cys 35 40 45 Ala Ala Asn Tyr Met Met Gly Asn Glu Leu Thr Phe Glu Asp Asp Ser 50 55 60 Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val Asn Leu Thr Ile Gln 65 70 75 80 Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile Cys Gln Val Glu Leu 85 90 95 Met Tyr Pro Pro Pro Tyr Tyr Leu Gly Ile Gly Asn Gly Thr Gln Ile 100 105 110 Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser Asp Gln Glu Pro Lys 115 120 125 Ser Ser Asp Lys Thr His Thr Ser Pro Pro Ser Pro Ala Pro Glu Leu 130 135 140 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 145 150 155 160 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 165 170 175 Ser His Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 180 185 190 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser 195 200 205 Thr Phe Arg Val Val Ser Val Leu Thr Val Val His Gln Asp Trp Leu 210 215 220 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ala 225 230 235 240 Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Gln Pro Arg Glu Pro 245 250 255 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 260 265 270 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 275 280 285 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 290 295 300 Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 305 310 315 320 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 325 330 335 Val Leu His Glu Ala Leu His Ser His Tyr Thr Gln Lys Ser Leu Ser 340 345 350 Leu Ser Pro Gly Lys 355 <210> 39 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Glycine-serine polymer linker <400> 39 Gly Ser Gly Gly Ser 1 5 <210> 40 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Glycine-serine polymer linker <400> 40 Gly Gly Gly Gly Ser 1 5 <210> 41 <211> 4 <212> PRT <213> Artificial sequence <220> <223> Glycine-serine polymer linker <400> 41 Gly Gly Gly Ser 1

Claims

1. An immunoadhesin comprising a first domain comprising a variant CTLA4 compared to SEQ ID NO:6 and a second domain comprising an IgG Fc region, wherein the variant CTLA4 is obtained by making an amino acid substitution in SEQ ID NO:6 selected from the following: A29H, A29H / K93Q and A29H / L61E / K93Q, wherein the variant CTLA4 provides enhanced binding to B7-1, B7-2, or both B7-1 and B7-2 compared to SEQ ID NO:

6.

2. A nucleic acid molecule encoding the immunoadhesin of claim 1.

3. A host cell comprising the nucleic acid molecule of claim 2.

4. A method for preparing a medicament, said method using the host cell of claim 3 under conditions whereby an immunoadhesin is produced.